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ABSTRACT 
Inflammation is a beneficial self-defense mechanism that is usually triggered by 
injury or infection and is designed to return the body to homeostasis. However, 
uncontrolled inflammation can be deleterious and has been shown to be involved in the 
etiology of several diseases, such as inflammatory bowel disorder, rheumatoid arthritis 
and asthma. Inflammation is counter-balanced by host-derived anti-inflammatory immune 
responses of the body thereby maintaining immune homeostasis. Millions of bacteria 
categorized under commensal (non-pathogenic), probiotic (mutualistic) and pathogenic 
(disease causing) species that inhabit gastro-intestinal (GI) tract of mammalian host have 
been reported to influence host immune homeostasis. Host immune response is tolerant 
towards beneficial bacteria and provide them with shelter and food, in turn these bacteria 
help the host by digesting carbohydrates and proteins and preventing colonization of GI 
tract by invading pathogens and potentially harmful indigenous bacteria. Intestinal 
microbiota-derived indole has been shown to exhibit anti-inflammatory properties by 
down regulating inflammatory markers. A shift in indigenous bacterial population 
(dysbiosis) has been recently found to initiate and perpetuate chronic inflammation 
resulting in the etiology of inflammatory bowel diseases (comprising ulcerative colitis and 
Crohn’s disease). However, the inter-play between pro- and anti-inflammatory signaling 
as well as molecular mechanism involved in host-microbiota interactions are not fully 
understood.  
In this dissertation, we developed a mathematical model to describe integrated pro- 
and anti-inflammatory signaling in macrophages. The model incorporates the feedback 
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effects of de novo synthesized pro-inflammatory (tumor necrosis factor α; TNF-α) and 
anti-inflammatory (interleukin-10; IL-10) cytokines on the activation of the transcription 
factor named nuclear factor -κ B (NF-κB) under continuous lipopolysaccharide (LPS) 
stimulation (mimicking bacterial infection). In the model, IL-10 upregulates its own 
production (positive feedback) and also downregulates TNF-α production through NF-κB 
(negative feedback). In addition, TNF-α upregulates its own production through NF-κB 
(positive feedback). We validated the mathematical model predictions by measuring 
phosphorylated NF-κB, de novo synthesized TNF-α and IL-10 in murine RAW 264.7 
macrophages when exposed to LPS. This integrated model was used to incorporate 
bacteria-derived indole signaling through a potential aryl hydrocarbon receptor (AHR) 
activated signal transduction pathway in human intestinal epithelial HCT-8 cells. The 
work described in this dissertation is a step towards modeling integrated pro- and anti-
inflammatory immune responses in host (intra-kingdom signaling) and their cross-talk 
with intestinal microbiota-derived metabolite (inter-kingdom signaling) to maintain 
homeostasis in the body.  
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IL-10 Interleukin 10 
NF-κB Nuclear Factor- kappa B 
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CHAPTER I  
INTRODUCTION 
1.1 BACKGROUND 
The human immune system is a highly complex network of organs, cells and 
biochemical mediators that work in conjunction with each other to prevent entry of foreign 
particles, spread of infection and is primarily designed to return the body to homeostasis. 
Acute inflammation (visibly perceived as tissue swelling and localized redness in case of 
external injuries or internal cytotoxicity leading to cell apoptosis in case of exposure to 
environmental pollutants such as dioxin) is the first wave of immune response post injury 
in multicellular eukaryotic organisms. It can be defined as a self-defense mechanism of 
the body, targeted towards protecting broken epithelial layer (at the site of injury) from 
microbial invasion and also spread of infection from food and airborne pathogens. 
Circulating blood comprises immune cells such as macrophages, dendritic cells, 
neutrophils, T lymphocytes and B lymphocytes that pick up cues of pathogenic invasion 
and eradicate invading pathogens, protect injured tissue from further insult and prevent 
spread of infection to other parts of the body. Inflammation is a double-edged sword. As 
indispensable as acute inflammation is, chronic inflammation can result in the body 
attacking its own cells even in absence of pathogens, which leads to autoimmune and 
inflammatory disorders such as rheumatoid arthritis (inflammation of small diarthrodial 
joints) [1], asthma (inflammation of respiratory tract) [2], psoriasis (inflammation of skin) 
[3], multiple sclerosis (inflammation of myelin sheath of nerve cells) [4] and inflammatory 
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bowel disorder (IBD) classified as ulcerative colitis (distal gastro-intestinal inflammation) 
and Crohn’s disease (pan gastro-intestinal inflammation) [5]. Under healthy conditions, 
pro-inflammatory responses are counter-balanced by anti-inflammatory responses to 
maintain homeostasis (equilibrium) in the body. However under disease conditions, the 
fine balance between pro- and anti-inflammatory responses is disturbed (or lost) and the 
resulting uncontrolled inflammation leads to pathogenesis of autoimmune and auto-
inflammatory disorders [6].  
Pro-inflammatory responses of immune and epithelial cells are marked by 
extracellular secretion of pro-inflammatory cytokines such as tumor necrosis factor alpha 
(TNF-α) and interleukin 8 (IL-8) on recognition of inflammatory cues like 
lipopolysaccharide (LPS) of bacterial cells through specialized cell surface receptor called 
toll-like receptor 4 (TLR4) [7].  The de novo synthesis of these cytokines is regulated by 
the transcription factor nuclear factor kappa B (NF-κB) which is sequestered as an inactive 
complex in the absence of inflammatory signals. Pro-inflammatory responses on the other 
hand are regulated and mitigated by anti-inflammatory cytokines such as interleukin 10 
(IL-10) which inhibit de novo synthesis of TNF-α and IL-8 through NF-κB down 
regulation [8]. 
For a long time the sole function of sophisticated immune responses was thought 
to be eradication of invading microbes however, recently a whole new facet of the 
mammalian immune response, i.e., tolerance towards indigenous microflora has been 
unraveled. Bacteria, bacteriophages, viruses and fungi inhabit different parts of the 
mammalian body such as oral cavity, ear, skin, urogenital tract and most prominently the 
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gastro-intestinal (GI) tract (especially the large intestine) [9]. In humans, microbial cell 
population exceeds the number of host cells by a factor of ten [10], thereby constituting 
90% of the cumulative genes of the host-microbiota system. The human GI tract houses 
approximately 1014 bacterial cells belonging to approximately 1000 different species of 
commensal (non-pathogenic), probiotic (mutualistic) and pathogenic (disease causing) 
bacteria in close proximity to host cells [11].  
The continuous exchange of signals between endogenous microbial community 
and host cells make the GI tract a classic example of intra- and inter-kingdom signaling 
ecosystem. The host immune response is extremely tolerant towards the non-pathogenic 
bacteria as opposed to the pathogenic ones. The specific host immune tolerance towards 
non-pathogenic species indicates a co-operative relationship between host and its 
beneficial microbiota (comprising commensal and probiotic bacteria) [12]. A primary 
function of the beneficial microbiota is preventing colonization of the GI tract by 
exogenous pathogenic bacteria or even potentially harmful indigenous microorganisms  
by directly competing with them for limited nutrients as well as by modulating host 
immune response [13] (Figure 1). Dysbiosis (alteration in microbiota population triggered 
by genetic pre-disposition or environmental factors), has been reported to be associated 
with the etiology of auto-inflammatory disorders such as inflammatory bowel disease 
(IBD) [14,15] (Figure 1). The intestinal microbiota’s involvement in digestion and 
metabolism of carbohydrates, synthesis of vitamins and recently discovered contribution 
in host immunity have made researchers term it as a novel organ in mammals [16]. 
 4 
 
 
Figure 1. Immunoregulation by intestinal microbiota. 
 
 
 
 
Although intestinal microbiota has been reported to have beneficial effects on the 
host, molecular mechanisms involved in signal transduction pathways activated by 
bacteria-derived molecules in host cells and the subsequent cross-talk between host-
derived pro- and anti-inflammatory signaling are not well understood. The main focus of 
this work is investigating pro- and anti-inflammatory responses in host immune cells, 
specifically macrophages, under chronic inflammatory signal exposure and bacterial 
metabolite indole-induced signaling in host intestinal epithelial cells in the context of host 
GI homeostasis. The dissertation is divided into two sections; first, development of a 
mathematical model describing pro- and anti-inflammatory immune signaling in 
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macrophages under chronic inflammatory signal exposure (in the context of overall 
immune homeostasis) and second, extending this model to studying the effects of host-
microbiota interactions for inflammatory signaling in intestinal epithelial cells in the 
context of GI immune homeostasis under the conditions of chronic inflammation 
(mimicking IBD). 
1.2 MOTIVATION 
Patients suffering from chronic inflammatory disease like IBD have diarrhea, 
rectal bleeding, abdominal pain, fatigue, and weight loss problems on a regular basis. All 
of these restrict the quality of life to a severe extent, trigger emotional stress and pose 
financial burden. It is a life-long ailment that currently has several treatments but no cure 
for absolute remission. According to Crohn’s and Colitis Foundation of America (CCFA) 
funded by Centers for Disease Control and Prevention (CDC), 70,000 new cases of IBD 
are diagnosed every year in the United States of America, among which 38,000 are cases 
of ulcerative colitis (UC) and 33,000 of Crohn’s disease (CD) with a median age for 
diagnosis of UC and CD being 34.9 and 29.5 years respectively. In USA, approximately 
1.6 million people are currently affected by IBD and 5% are less than 20 years in age. IBD 
diagnosed in children is more severe than that diagnosed in adults [17] and often causes 
delayed puberty and growth failure [18]. CCFA reports that in 2010 187,000 patients were 
hospitalized for CD and 107,000 for UC. The root cause for the incidence of such disorders 
is not completely known, however, besides genetic pre-disposition, environmental factors 
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such as lifestyle, diet, and gut microbiota are found to play an important role in the etiology 
of IBD [19].  
The medications currently available for treatment of IBD cause non-specific 
suppression of immune response, e.g., corticosteroids that inhibit ability of the body to 
initiate and sustain inflammatory responses [20]. Corticosteroids are prescribed to patients 
only for short-term control of flare-ups and not recommended for long-term use because 
of their strong side effects associated with bone loss, weight gain, cataracts, sleep 
disturbance and mood swings. On the other hand immunomodulators such as 6-
mercaptopurine, azathioprine and methotrexate are prescribed to patients in remission who 
have only responded to steroids [21]. Amino salicylates (introduced orally or rectally) help 
reduce inflammation of the intestinal wall, however, is effective in ulcerative colitis only 
and not in the case of Crohn’s disease [22,23]. The latest development in the treatment for 
IBD is the use of targeted inhibitors such as infliximab (approved by FDA for treatment 
of CD in 1998 as intravenous infusion) [24], golimumab (approved by FDA for treatment 
of UC in 2013 as subcutaneous injection) [25] which are monoclonal antibodies against 
tumor necrosis factor alpha (TNF-α), a major pro-inflammatory cytokine (description in 
section 2.3.2.1). Vedolizumab (approved by FDA for treatment of UC and CD in 2014) is 
a monoclonal antibody against lymphocytes, preventing them from entering inflamed 
tissues [26]. In cases of severe UC and CD, intravenous infusions are prescribed every 4-
6 weeks along with regular intake of immunomodulators like 6-mercaptopurine. IBD 
patients resort to surgical methods when no medication seem to relieve their discomfort. 
By means of surgery the affected regions of GI tract (usually large intestine) are amputated 
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or in severe cases large intestine is completely removed and the ileum (distal end of small 
intestine) is brought out onto the surface of the abdominal skin creating an opening for the 
passage of intestinal waste to be collected in a pouch outside the body [27,28]. All these 
procedures force the patient to adopt a drastic lifestyle change. 
Most of the current IBD treatments focus at immunosuppression either for short-
term remission of flare-ups or for keeping symptoms under control. For complete non-
invasive cure of IBD, we still need to understand the root cause behind the etiology of the 
disease and design therapy that keeps pro-inflammatory responses in check but does not 
suppress them completely. Clinically IBD is identified as ulcerations at the small or large 
bowel mucosa [19]. Although genetic pre-disposition influences prevalence of the disease, 
recent research has established that environmental factors are essential for the 
pathogenesis and growing incidence of IBD all over the world [19].  Diet, prolonged use 
of antibiotics and microbial exposure during childhood and adulthood have been reported 
to be in direct relation with incidence of IBD [19]. Moreover, all these factors modify 
intestinal microbiota to a great extent, thereby indicating that a shift in normal microbiota 
population can play a critical role in the pathogenesis and perpetuation of IBD [19]. Bansal 
et al. reported that bacterial metabolite, for example, indole (released by endogenous 
bacteria upon tryptophan metabolism) has the potential to down regulate pro-
inflammatory signals, such as NF-κB (transcription factor) and IL-8 (chemokine) and 
induce anti-inflammatory signals such as IL-10 (cytokine) [29] in human intestinal 
epithelial cells.  
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Knowledge of the co-operative relationship between host and intestinal microbiota 
[12,15,16] and the possibility that the microbiota can exert anti-inflammatory effects on 
the host [29,30] laid the foundation for this work. This dissertation aims at understanding 
the host-microbiota interactions in the context of immune regulation in the GI tract using 
a systems biology approach. We developed experimentally validated mathematical 
models to study intra-host pro- and anti-inflammatory immune responses induced by 
bacterial LPS in macrophages and bacteria-derived metabolite indole signaling through a 
potential signal transduction pathway that influences immune responses of human 
intestinal epithelial cells.  
1.3 RESEARCH OBJECTIVES, IMPORTANCE AND NOVELTY 
Biochemical interactions among different components of a biological signaling 
network is highly complex and difficult to comprehend solely through experimental 
studies. Mathematical modeling of such biological networks expands the opportunity to 
infer experimental data and understand network interactions in a much broader context. 
The deterministic computational models developed in the current work in conjunction 
with experimental data are composed of important biochemical reactions (represented in 
the form of ordinary differential equations using MATLAB) of signal transduction 
pathways corresponding to LPS and TNF-α stimulation, involving transcription factor 
activation and subsequent cytokine synthesis that can help elucidate molecular 
mechanisms associated with regulating immune homeostasis in host. Host-microbiota 
interactions have been reported to have profound effect on host homeostasis and thus 
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investigating mechanistic dynamics of these interactions computationally and 
experimentally can shed some light on the pathogenesis of several inflammatory diseases. 
Microbiota-derived indole has been reported to regulate inflammation in host, however, 
the molecular mechanism involved in indole signaling is not clearly understood. This 
dissertation focuses at investigating a possible molecular mechanism of indole-induced 
signal transduction that influences pro- and anti-inflammatory immune responses of the 
host. We developed experimentally validated computational models that can predict host 
responses in the context of immune homeostasis for conditions that are not experimentally 
achievable due to lack of suitable techniques or resources. We selected essential 
biochemical reactions involved in the signal transduction pathway that are experimentally 
verifiable to reduce uncertainty in the values of reaction parameters. The biochemical 
network of host immune responses and host-microbiota interactions as mentioned in 
sections 1.1 and 1.2 comprise several feed-forward and feed-back regulatory loops that 
influence the overall outcome of the biological reactions. We incorporated known 
regulatory feed-back loops in our deterministic models, something which has not been 
done before. Most of the deterministic computational models that have been developed so 
far in the context of inflammation have either considered synthesis of only one pro-
inflammatory cytokine [31,32] or represented stimulatory effects of multiple extracellular 
cytokines [33]. In this work we studied cross-talk between de-novo synthesized pro-
inflammatory cytokine and anti-inflammatory cytokines in murine macrophages under 
continuous LPS stimulation and the effect of indole on immune responses of human 
intestinal epithelial cells under continuous TNF-α stimulation. The models developed here 
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are a step towards assimilating our knowledge on host-derived pro- and anti- inflammatory 
immune responses as well as intra- and inter-kingdom signaling as studied in mammalian 
gastro-intestinal tract. The experimental data obtained and mathematical models 
developed in this work provide a quantitative and dynamic profile of the cytokines and 
transcription factors involved in the signal transduction pathways studied.  
The specific objectives of this work are: 
 Development of a computational module representing pro-inflammatory immune 
response in macrophages induced by lipopolysaccharide (LPS) resulting in activation 
of NF-κB signal transduction pathway and de novo synthesis of TNF-α positive 
feedback effect of TNF-α on NF-κB activation. 
 Development of an anti-inflammatory module representing LPS-induced de novo 
synthesis of anti-inflammatory cytokine (IL-10) through NF-κB and STAT3 activation 
and positive feedback effect of IL-10 on STAT3 activation and negative feedback 
effect on NF-κB. 
 Assimilation of pro- and anti-inflammatory modules as described above into an 
integrated immune response model where TNF-α synthesis is inhibited by IL-10 
through down regulation of NF-κB activation. 
 Extension of the above integrated model to incorporate indigenous bacterial metabolite 
indole and predict its effect on NF-κB activation and de novo IL-8 synthesis in human 
intestinal epithelial cells. 
 Investigation of a possible signal transduction pathway to mediate indole-induced 
immune responses in host. 
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CHAPTER II 
LITERATURE REVIEW 
2.1 MAMMALIAN IMMUNE RESPONSE 
Mammalian immune response is mediated through an intricate network of 
lymphoid organs (thymus, bone marrow, spleen, lymph nodes and tonsils), different cell 
types (dendritic cells, macrophages, neutrophils, T-cells, B-cells and more), messenger 
molecules (cytokines) and humoral factors (antibodies, complement proteins and 
antimicrobial peptides) that protect the body from foreign entities such as bacteria, viruses, 
and fungi that might invade through broken skin at the site of injury or airborne and 
foodborne pathogens. The response of the immune system can be broadly classified into 
two categories on the basis of speed and specificity of action, namely innate and adaptive 
immune response. Disruption in innate immune responses can lead to auto-inflammatory 
diseases such as IBD [34], whereas, hyperactive adaptive immune responses result in 
autoimmune diseases, allergy and allograft rejection [35]. 
2.1.1 Innate immune response in mammalian host 
Innate immune responses are initiated immediately after injury and are primarily 
mediated through dendritic cells, macrophages, neutrophils, eosinophils, leukocytes, mast 
cells, monocytes and natural killer cells. These cells circulate in blood and are localized 
in specific niches of different organs such as liver [36], spleen (which stores half the 
body’s monocytes that differentiate into dendritic cells and macrophages upon tissue 
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injury) [37] and Peyer’s patches (specialized lymphoid nodules adjacent to epithelial cell 
layer in ileum) [38]. Innate immune response is a defense mechanism that has been 
conserved through evolution in plants and animals (invertebrates and vertebrates) [35] 
which indicates its presence even before the split of the two kingdoms.  
Communication between different cell types of innate immune system is 
accomplished through biochemical messenger molecules called cytokines like tumor 
necrosis-factor alpha (TNF-α), interferon gamma (IFN-γ) and interleukin 8 (IL-8). Though 
the innate immune response is immediate post injury and an indispensable part of the 
immune system, it damages some of the host cells due to its lacks of specificity. However, 
innate immune cells like dendritic cells, macrophages and neutrophils can differentiate 
between self and non-self entities on the basis of specialized structures present on 
microbial cells called pathogen-associated-membrane-proteins (PAMPs), for example, 
flagellin of bacterial flagella [39], lipopolysaccharides (LPS) of gram negative bacteria 
and peptidoglycan of gram positive bacteria [35] that can trigger an immune response.  
Resting macrophages are activated by both bacterial as well as host-derived 
inflammatory signals such as LPS and pro-inflammatory cytokines like TNF-α 
respectively. Macrophages respond by releasing more pro-inflammatory cytokines and 
phagocytizing pathogens [40]. The central feature of innate immune response is the 
activation and recruitment of specialized neutrophils to the site of injury to phagocytose 
pathogens [41]. Phagocytizing neutrophils and macrophages extend their cytoplasmic 
membranes to form pseudopodia which in turn form phagosomes (membrane bound 
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vesicles) around the targeted particles which in turn fuse with lysosomes and to form 
phagolysosome that can lyse the microbe, as shown in Figure 2.  
 
 
 
 
 
 
Figure 2. Phagocytosis of microbes by macrophages and neutrophils: an integral part of 
innate immune response [42]. 
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Dendritic cells are found in circulation as well as in tissues that have contact with 
external environment such as skin, outer lining of nose, lungs and gastro-intestinal tract 
[43]. Due to their specific location close to the external environment they are usually the 
first ones to sample the surrounding with their extendable dendrite-like structures that can 
protrude through intracellular spaces of the epithelial lining. Dendritic cells are antigen-
presenting cells that process antigen material upon sampling the environment and present 
them to B and T lymphocytes in lymph nodes. Immature dendritic cells circulating in 
blood upon activation migrate to lymph nodes and interact with T and B lymphocytes to 
induce adaptive immune response [43]. Dendritic cells thus link the innate and adaptive 
immune responses.  
2.1.2 Adaptive immune response in mammalian host 
Invertebrates and simpler animals defend themselves from pathogens by virtue of 
their protective barriers, phagocytic cells and secretion of toxic molecules, much similar 
to the innate immune system of vertebrates. However, adaptive immune system is a 
characteristic feature of vertebrates [35]. It is called upon when innate immune responses 
are not sufficient to eradicate pathogenic invasion [35]. It is mediated by two types of 
lymphocytes, namely, B and T cells, and unlike innate immune responses, adaptive 
responses are highly specific to the type of pathogen invading the body (can differentiate 
proteins on the basis of single amino acid or distinguish between optical isomers of the 
same molecule). Adaptive immune responses can be regarded as the second wave of 
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protective immune response, called upon by the innate immune system and is effective 
only if the body has been exposed to the pathogens a priori [43].  
The adaptive immune response can be further classified under two categories, 
antibody mediated responses (regulated by B lymphocytes) and cell mediated responses 
(regulated by T lymphocytes). B cells are activated by innate immune cells to secrete 
antibodies called immunoglobulins targeted to bind specific pathogens (antigens) and 
render them inactive. Antibody bound inactive pathogens are marked for phagocytic 
elimination by innate immune cells. On the other hand, T-cells can detect pathogens inside 
the host and either kill the infected cells themselves or secrete signaling molecules to 
activate phagocytizing cells like macrophages to eliminate the pathogen. 
2.1.3 Pro-inflammatory immune response 
Visibly, inflammation is swelling and redness around injured tissues due to 
increased blood flow to the site of injury. Secretion of pro-inflammatory cytokines by host 
cells such as TNF-α, IFN-γ, interleukin 1-beta (IL-1β) and chemokine IL-8 under bacterial 
stimulation are indicators of pro-inflammatory responses. A broad range of cell types such 
as macrophages, T lymphocytes, B lymphocytes, mast cells, endothelial cells and 
fibroblasts release such cytokines. Cytokines are extremely potent signaling molecules 
and vary in size between 8 and 30 kDa. The de novo synthesis of cytokines in immune 
cells upon pro-inflammatory signal activation is regulated by transcription factors. 
Nuclear factor kappa B (NF-κB; described in section 2.3.3.1) is one of the most abundant 
transcription factors that mediate pro-inflammatory responses and induce synthesis of 
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TNF-α, IL-8, and IL-1β [44]. The major sources of pro-inflammatory cytokines are Th-1 
type cells that secrete high levels of IL-1, TNF-α and IFN-γ that in turn activate 
macrophages and induce innate immune responses against invading pathogens [45]. Other 
transcription factors that are involved in pro-inflammatory responses are signal transducer 
and activator of transcription (STAT3), activator protein 1 (AP-1) and nuclear factor of 
activated T cells  (NFAT) [46]. Acute pro-inflammatory responses of the innate immune 
system play an integral role in self-defense, however uncontrolled inflammatory responses 
can lead to the etiology of auto-inflammatory disorders like intestinal bowel disease 
(IBD). In healthy conditions, pro-inflammatory responses are counter balanced by anti-
inflammatory responses to maintain homeostasis in the body. 
2.1.4 Anti-inflammatory immune response 
The prominent anti-inflammatory cytokines that play integral role in maintaining 
homeostasis in the body are interleukin 10 (IL-10) and tumor growth factor beta (TGF-β). 
IL-4, IL-13, and IL-1 receptor antagonist (IL-1ra) are other well-known anti-inflammatory 
cytokines that are mostly secreted by Th-2 type cells [45]. Regulatory T cells (Treg cells) 
formerly known as suppressor T cells are a subpopulation of T cells that modulate pro-
inflammatory responses of the immune system and maintain tolerance towards self-
antigens. Treg cells are a source of IL-10 and TGF-β [47]. Macrophages, an integral part 
of the innate immune response exhibit dual phenotype classified as M1 and M2 [48]. M1 
is the pro-inflammatory phenotype that is activated by inflammatory signals and secrete 
pro-inflammatory cytokines such as TNF-α, IL-1β and IFN-γ. On the other hand, the M2 
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phenotype exhibits anti-inflammatory responses marked by de novo synthesis and 
secretion of IL-10, IL-4 and IL-13 [49] as shown in Figure 3. IL-10 and TGFβ secreted by 
intestinal epithelial cells and resident macrophages play an important role in maintaining 
homeostasis in the host gastro-intestinal (GI) tract which is inhabited by ~1014 bacterial 
cells. 
 
 
  
  
 
Figure 3. M1 (pro-) and M2 (anti-inflammatory) macrophage activation and responses. 
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2.2 HOST-MICROBIOTA INTERACTIONS IN GASTRO-INTESTINAL TRACT 
A dynamic interaction exists between host immune cells and the microorganisms 
that colonize the gastro-intestinal (GI) tract. The intestinal microbiota is embedded in the 
mucous layer adjacent to the intestinal epithelial lining as shown in Figure 4. Colonization 
of GI tract by microbiota is initiated by maternally acquired bacteria during birth followed 
by large number of microflora that are acquired from the environment [15]. The 
microbiota composition varies between individuals; however, the two major bacterial 
phylotypes are Firmicutes ssp. and Bacteroidetes spp. [50], and are mostly gram negative 
anaerobes [51].  
 
 
 
 
 
 
Figure 4. Cross-sectional view of mammalian gastro-intestinal tract. 
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Not much is known about the composition and functions of the intestinal 
microbiota, as almost 80% of the microbiota cannot be cultivated in vitro in the laboratory 
[51]. The indigenous microbiota anaerobically converts undigested carbohydrates and 
proteins in the large intestine to short chain fatty acids such as acetate, propionate, butyrate 
[52] that have been reported to induce T cell differentiation into Treg cells and promote 
secretion of the anti-inflammatory cytokine IL-10 [53]. Host-microbiota mutualistic 
relationship is represented in the fermentation of undigested dietary components by the 
microbiota to produce energy from carbohydrates and proteins that might have been 
discarded by host, which in turn promotes growth and sustenance of microbiota. The 
intestinal microbiota is referred to as a virtual organ by some authors due to its 
multifaceted metabolic and immunomodulatory functions [54]. Its activity depends 
largely on substrate availability and its retention time before being discharged out of the 
body with intestinal waste [52]. Other than metabolic functions, intestinal microbiota has 
been found to modulate mucosal immune response and colonization by invading 
endogenous pathogens and potential harmful indigenous bacteria [13]. 
Immune cells in the GI tract are located in specialized lymphoid tissues such as 
GALT (gut associated lymphoid tissue), ILT (intestinal lymphoid tissue) and Peyer’s 
patches (usually in ileum of small intestine as shown in Figure 5). 
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Figure 5. Small intestine organization. 
 
 
 
 
The intestinal epithelial lining forms a boundary between host cells and bacterial colonies 
and are interspaced with specialized M-cells that allow passage of selective molecules 
between host and the bacterial compartments [55].  The close proximity of different cell 
types and molecules made by them, as well as exchange of molecules between host and 
microbiota [56] facilitates intra- and inter-kingdom signaling. Previous studies have 
shown that both the microbiota and intestinal epithelial cell responses are altered by 
molecules produced by the other cell type. For example, previous work from our 
laboratory showed that norepinephrine (hormone) released by host cells affects bacterial 
colonization and virulence [57]; similarly, indole produced by the microbiota modulates 
indicators of inflammation in intestinal epithelial cells [29]. 
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2.2.1 Microbiota-derived indole as an inter-kingdom signaling molecule  
Escherichia coli, one of the bacteria found in mammalian GI tract produces 
~600µM indole in suspension culture [58] and it has also been detected in feces at 
comparable concentrations [59,60]. E. coli, possesses tnaA and tnaB genes which encode 
for enzyme tryptophanase A (TnaA) and transporter protein TnaB. TnaB helps in 
internalizing dietary tryptophan (amino acid) which then gets hydrolyzed by TnaA to 
produce indole, pyruvate and ammonia [61,62] as shown below: 
 𝐿 − 𝑇𝑟𝑦𝑝𝑡𝑜𝑝ℎ𝑎𝑛 + 𝑤𝑎𝑡𝑒𝑟 ↔ 𝐼𝑛𝑑𝑜𝑙𝑒 + 𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 𝐴𝑚𝑚𝑜𝑛𝑖𝑎  
Unlike tryptophan, it is not clearly known if indole readily diffuses through the 
cell membrane or if it requires a transport complex to facilitate its uptake and secretion 
[62]. Indole had been identified as a bacterial metabolite as early as in the 19th century and  
was regularly used as a test for distinguishing cholera spirilla from other spirilla [63]. 
However, only recently has indole been recognized as an intercellular signaling molecule 
that regulates diverse physiological processes in bacteria such as motility [57], biofilm 
formation [57], antibiotic resistance (by inducing xenobiotic exporter genes) [64] and 
virulence [65] as well as increases intestinal epithelial tight junction resistance and 
attenuates pro-inflammatory responses in host by downregulating NF-κB under 
continuous TNF-α stimulation in vitro [29]. This makes indole an important intercellular 
signaling molecule that influences both bacterial as well as host responses, thereby 
shaping host-microbiota crosstalk. Almost 85 species of gram positive and gram negative 
bacteria are known to produce indole including certain pathogenic bacteria such as 
Bacillus alvei, Vibrio cholera, several Shigella strains, Enterococcus faecalis and 
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pathogenic E. coli [62]. However, it is not known if indole concentrations vary between 
healthy and diseased individuals.  
Several non-indole producing bacteria and host cells in the GI tract and liver 
possess genes that can convert indole to produce several derivatives such as indole-3-
propionic acid (identified as a powerful anti-oxidant), indoxyl sulphate [66] and 5-
hydroxyindole [67]. These derivatives have also been identified by our laboratory in 
luminal contents [68] indicating its potential contribution in systemic immune response. 
The anti-inflammatory properties of indole (as an inhibitor of NF-κB and down regulator 
of IL-8) as reported by previous work from our laboratory [29] makes it a potential 
therapeutic candidate for inflammatory bowel disease. However, the molecular 
mechanisms underlying the reported effect of indole are not known. In order to study the 
effect of indole in modulating chronic inflammation in host and its potential contribution 
as a therapeutic molecule, it is necessary to identify and characterize the signal 
transduction pathways involved and its interaction with other pro- and anti-inflammatory 
signaling pathways in host cells. 
2.3 SIGNAL TRANSDUCTION 
Signal transduction refers to the biological process of conveying an extracellular 
signal from the cell membrane to the intracellular nucleus to activate target genes by 
stimulating or inhibiting cytosolic proteins in a specific order. Immune responses are 
examples of signal transduction where an extracellular stimulus such as bacterial 
membrane component LPS triggers pro-inflammatory responses by activating 
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transcription factor (such as NF-κB) that leads to transcription and de novo synthesis of 
TNF-α. 
 Cytokines (TNF-α, IL-8, IL-10 and more), hormones (estrogen, melatonin and 
more) and neurotransmitters (serotonin, acetylcholine and more) are usually the 
extracellular signals that initiate communication between different cell types in an 
organism. MEDLINE (Medical Literature Analysis and Retrieval System Online, or 
MEDLARS Online), a medical bibliographic database reported the first entry of the term 
“signal transduction” in 1972. Some early articles used “signal transmission” and “sensory 
transduction” to explain present day signal transduction phenomena [69,70]. Signal 
transduction pathways started getting attention from researchers post late 1980s following 
advancement in experimental techniques to test complex biochemical interactions. The 
first step in signal transduction pathway is the recognition of extracellular signaling 
molecule (ligand) by its corresponding receptor on the surface of a cell. Ligand-receptor 
binding leads to conformational change of receptor that triggers cascade of subsequent 
intracellular biochemical reactions. The essential components of a signal transduction 
pathway are the ligands, the cell surface receptors, intracellular proteins that affect the 
functioning of the cell, target genes and proteins. 
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2.3.1 Cell surface receptors 
 Usually cell surface receptors are transmembrane proteins with extracellular, 
transmembrane and intracellular domains. An extracellular ligand binds to the 
extracellular domain of the receptor, changing the conformation of the transmembrane 
domain which in turn relays the effect to signaling proteins associated with the 
intracellular domain, without the need of internalizing the ligand. Cell surface receptors 
can be categorized into three classes based on their mode of relaying extracellular signal 
to the internal proteins of a cell, namely, ion-channel-linked receptor, G-protein-linked 
receptor and enzyme-linked receptor. These are expressed in very low numbers varying 
between a few hundred and few thousand per cell [71]. 
2.3.1.1 Ion-channel-linked receptors 
These receptors are usually associated with neuronal signaling in excitable cells 
such as neurons, muscle cells and touch receptor cells where chemical signal (e.g., 
acetylcholine) or mechanical signal (e.g., touch) is converted to electrical signal. Ion-
channel linked receptors are multimeric transmembrane proteins that undergo 
conformational change when a ligand binds to them such that an opening is created 
through the cell membrane to allow passage of ions such as sodium (Na+) and potassium 
(K+) as shown in Figure 6 (A). Flow of ions through the channel in the receptor alters the 
charge across the cell membrane thereby creating an electrical signal. These receptors are 
specific with regard to the type of ion that flows through their opening. The ions channels 
are open only for few milliseconds, past which the ligands dissociate from the receptor 
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and the ion channels enter a resting stage, unresponsive to signals for a short period of 
time. 
2.3.1.2 G-protein-linked receptors 
These receptors are also called seven transmembrane domain receptors (7TM 
receptors) as they traverse the cell membrane seven times, as shown in Figure 6 (B). The 
commonly known ligands for this receptor are hormones, neurotransmitters and 
pheromones. Most of the chemokine receptors, for example, receptor for IL-8 (CXCR1) 
is of this type [72]. The receptor is associated with 3 G proteins, α, β and γ that are 
physically connected in a preformed complex. In an unstimulated state, the receptor and 
G proteins are inactive. Extracellular ligand binding induces conformational change of the 
receptor which in turn alters conformation of α subunit that allows it to exchange its 
guanosine-diphosphate (GDP) for guanosine-triphosphate (GTP). Activated α subunit 
separates from βγ complex, both of which can then activate target proteins in the plasma 
membrane. After α subunit activates its target proteins, it inactivates itself by hydrolyzing 
its bound GTP to GDP. Inactive α subunit then re-associates with βγ to form an inactive 
G protein. 
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Figure 6. Different cell surface receptors found in mammals. (A) Ion-channel-linked 
receptor, (B) G- coupled receptor, (C) Enzyme-linked receptor [73]. 
 
 
 
 
2.3.1.3 Enzyme-linked receptors 
 Enzyme-linked receptors are composed of single or multiple polypeptide domains 
that span the cell membrane once as shown in Figure 6 (C). The characteristic feature of 
these receptors are the association of their cytosolic domain with intracellular enzymes 
that either phosphorylate (kinase enzyme) or de-phosphorylate (phosphatase enzyme) 
proteins that are involved in the specific signal transduction pathway activated by the 
corresponding ligand. Most of the cytokine receptors that influence immune regulation are 
usually of the enzyme-linked type. Toll-like receptors (TLR) and TGFβ receptors are 
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examples of enzyme-linked receptors. Since the late 1980s, studies pertaining to cytokine 
receptors have significantly increased, owing to the successful large-scale bioprocessing 
and synthesis of recombinant cytokines [71]. In recent years, cytokine receptors have 
gathered considerable attention from investigators as their deficit in cells has been directly 
co-related to several immunodeficiency disorders due to alteration in signal transduction.  
2.3.2 Cytokines as extracellular messenger molecules 
Cytokines are important extracellular messenger molecules that constitute an 
integral part of immune response in vertebrates. Some of the cytokines that have been 
studied in this research work are TNF-α, IL-8 and IL-10.  
2.3.2.1 Tumor necrosis factor alpha (TNF-α) 
TNF-α is one of the most prominent pro-inflammatory cytokines that influences 
innate and adaptive immune responses. It belongs to the TNF superfamily of proteins that 
is composed of 19 members and 29 corresponding receptors which are characterized by 
cysteine rich residues in the extracellular domain [74]. It is known to be synthesized by 
macrophages, T lymphocytes, B lymphocytes, smooth muscle cells, endothelial cells, 
epithelial cells, adipocytes as well as fibroblasts [75]. In 1893, Coley et al. reported tumor 
necrotic activities of a biological factor in cancer patients who were exposed to several 
bacterial infections [76]. In 1975, Carswell et al. [77] reported that the tumor necrotic 
factor was TNF, currently known as TNF-α, a glycoprotein that is released into the blood 
in response to endotoxin (lipopolysaccharide from Escherichia  coli) treatment of mice 
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already primed with mycobacterium bovis strain Bacillus Calmette-Guérin (BCG) 
inoculation. Carswell et al. conjectured that TNF-α might be secreted by activated 
macrophages upon bacterial infection [77]. Later in 1985, Beutler et al. showed that TNF-
α synthesis could be i by endotoxin alone in absence of pathogen priming [78] and is 
secreted at detectable levels two hours post endotoxin stimulation. Lot of research has 
since been done on TNF-α and is currently considered a canonical pro-inflammatory 
signal that is associated with the pathogenesis of inflammatory bowel diseases [79,80].  
TNF-α has a molecular weight of 17 kDa [81] and is usually found as a trimer in 
solution and when bound to its receptor [82]. TNF-α trimers are at least 8-fold more active 
and have higher receptor binding affinity than their monomeric counterparts. TNF-α has 
two kinds of receptors, TNFR1 (55kDa) and TNFR2 (75kDa) which trigger different 
pathways when activated by ligand binding [83]. Few decades back TNF-α was considered 
as one of the candidates for cancer therapy due to its cytocidal effects on tumors [84]. 
However, clinical trials could not be completed owing to its systemic toxicity at effective 
concentrations [85]. Recently it has been  reported to play a significant role in etiology of 
type II diabetes, cancer, auto-inflammatory and autoimmune disorders [74]. TNF-α is a 
classical pro-inflammatory cytokine and prototypical activator of transcription factor NF-
κB, de novo synthesis of itself being induced by NF-κB, thereby indicating a positive feed-
back effect on its own production. TNF-α production has been shown to be inhibited by 
anti-inflammatory IL-10 [86]. 
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2.3.2.2 Interleukin 8 (IL-8) 
Cytokines that induce migration or “chemotaxis” of cells are called chemokines. 
Interleukin-8 (IL-8) is a chemokine that is secreted by macrophages, epithelial cells, 
endothelial cells and smooth muscle cells in response to an inflammatory signal. IL-8 is 
among the first chemokines identified and is also known as neutrophil chemotactic factor 
due to its function as an inducer of neutrophil, basophil and T lymphocyte migration 
towards the site of infection [87] . In addition, IL-8 also induces migrated cells to 
phagocytize invading pathogens. The characteristic feature of most chemokines is the 
presence of four cysteine residues and on the basis of the motif displayed by first two 
cysteine residues, they are categorized into four classes, namely, CXC (alpha), CC (beta), 
C (gamma) and CX3C (delta) [88]. IL-8 belongs to the CXC chemokine family comprising 
four members [87]. Chemokine receptors are usually of the G-protein coupled type, of 
which CXCR1 and CXCR2 bind IL-8 [88]. The synthesis of IL-8 is primarily regulated 
by transcription factor NF-κB [87]. However, response element pertaining to nuclear 
factor-interleukin 6 (NF-IL-6) has been characterized in the promoter region of IL-8 gene 
[89]. IL-8 is synthesized as a 99 amino acid peptide and is proteolysed to form several 
isoforms among which peptides comprising 72 (in immune cells) and 77 (in non-immune 
cells) amino acids are most biologically relevant [87]. IL-8 has a molecular weight of 8 
kDa and readily forms homodimer and even oligomers at higher concentrations in solution 
[90]. However, IL-8 monomer is the active form of the chemokine and is recognized by 
the receptor in the monomeric form [90,91]. Inflammatory signals such as TNF-α, IL-1, 
IL-6, lipopolysaccharide, reactive oxygen species and other cellular stresses can induce 
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synthesis and secretion of IL-8 whereas, IL-4 and IL-10 can inhibit IL-8 synthesis [87]. 
IL-8 has been reported to be involved in the pathogenesis of cancer autoimmune, 
inflammatory and infectious diseases [87,92]. 
2.3.2.3 Interleukin 10 (IL-10) 
IL-10 belongs to the IL-10 family of cytokines (consisting of nine members, e.g., 
IL-19, IL-20, IL-22, IL-24), members of which are closely related to interferon (IFN) 
family of cytokines [93]. IL-10 is a prominent anti-inflammatory cytokine that can repress 
pro-inflammatory responses by inhibiting synthesis of pro-inflammatory cytokines such 
as TNF-α and IL-8 [86,87]. IL-10 is mainly secreted by dendritic cells, macrophages, 
natural killer cells, mast cells, neutrophils, eosinophils, T lymphocytes (notably Treg cells) 
and B lymphocytes and targets primarily leukocytes [93]. IL-10 was first identified in 
1989 and reported by Fiorentino et al. as a “cytokine synthesis inhibitory factor (CSIF)”, 
based on its ability to inhibit synthesis of pro-inflammatory cytokines such as IL-2, IL-3, 
TNF-α, IFN-γ and granulocyte-macrophage colony stimulating factor (GM-CSF) [94]. 
Mature human and mouse IL-10 comprises 160 amino acids and binds to a chain of two 
receptors, IL-10R1 and IL-10R2 [93]. The association of IL-10 with IBD was first 
established in 1993 by Kühn et al. [95] where IL-10-deficient mice (Il10-/-) showed normal 
immune response during development but spontaneously developed colitis, marked by 
abnormal mucosal architecture and infiltration of leukocytes. This showed that bowel 
inflammation is a manifestation of uncontrolled immune response triggered by enteric 
antigens and IL-10 is an essential immunomodulator, especially for the gastro-intestinal 
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tract. Unlike other members of the IL-10 family of cytokines, IL-10 itself is prominent 
mainly during the recovery phase of inflammation and repairs cellular damage caused due 
to inflammation [93]. IL-10 activates transcription factor signal transducer and activator 
of transcription 3 (STAT3) and activated STAT3 itself triggers IL-10 transcription 
indicating a possible positive feed-back effect on IL-10 synthesis. 
2.3.3 Transcription factors in mammalian signal transduction 
According to the human genome sequencing data published in 2004, there are 
approximately 24,000 genes that encode proteins [96]. Gene expression is tightly 
controlled at multiple levels, and transcription factors are one such regulatory mechanism. 
Transcription factors are regulatory proteins that induce transcription of specific genes 
when activated by corresponding signals. They can regulate genes involved in immune 
response, growth, proliferation and other physiological functions of the body. Monitoring 
activation of transcription factors by corresponding stimuli gives a measure of the 
dynamics of the signal transduction pathway. 
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2.3.3.1 Nuclear factor-kappa B (NF-κB) 
Nuclear factor-kappa B (NF-κB) is a transcription factor that is found in almost all 
cell types and is known to mediate pro-inflammatory responses. It promotes anti-apoptotic 
functions, thereby maintaining tumors. In 1986, Sen et al. [97] discovered NF-κB in B-
cell tumors as a factor that bound to κ light chain enhancer with a sequence of 
GGGACTTTCC. In a follow-up study, Sen et al. [98] reported that lipopolysaccharide 
(LPS) or phorbol ester could induce activation of NF-κB in absence of protein synthesis, 
indicating NF-κB to be present in an inactive form prior to LPS stimulation. In 1988, 
Baeuerle et al. [99] described an inhibitory protein (IκB) that binds to cytoplasmic NF-κB 
and sequesters its activity. Baeuerle et al. also reported that phorbol ester treatment of 
lymphoblastoids could induce dissociation of inactive NFκB-IκB complex, thereby 
releasing NF-κB that can translocate into the nucleus to activate target genes as shown in 
Figure 7. NF-κB is a pivotal transcription factor and has been reported to be involved in 
in the pathogenesis of chronic inflammatory diseases [100]. NF-κB works in concert with 
other transcription factors to mediate immune responses in host cells. 
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Figure 7. Schematic representation of signal transduction pathway mediated by nuclear 
factor kappa B (NF-κB).  
 
 
 
 
2.3.3.2 Aryl hydrocarbon receptor (AHR) 
Aryl hydrocarbon receptor is a cytosolic ligand activated transcription factor that 
is known to bind to a large number of exogenous aromatic hydrocarbons such as dioxins, 
polyclyclic aromatic hydrocarbons (PAH), plant flavonoids and polyphenolics. The 
prototypic ligand for AHR is 2,3,7,8-tetracholorodibenzo-p-dioxin (TCDD, a by-product 
of industrial synthesis of herbicide) [101] and is known to regulate xenobiotic degrading 
enzymes such as cytochrome P450. AHR has been reported to be involved in regulatory 
T cell (Treg) differentiation and down regulation of pro-inflammatory responses and use of 
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natural AHR ligands (for example, plant flavonoids) have been reported as potential 
therapeutics for inflammatory disorder [102]. Microbiota-derived indole is an aromatic 
hydrocarbon and due to its structural similarity with AHR ligand TCDD as shown in 
Figure 8 it is hypothesized that indole could be a potential ligand for AHR and mediate 
immunoregulation of host through AHR activation. 
 
 
 
 
 
Figure 8. Aromatic ligands for aryl hydrocarbon receptor (AHR)  
(A) 2,3,7,8-tetrachlorodibenzodioxin (TCDD) – canonical AHR ligand; (B) indole – 
potential AHR ligand. 
  
 35 
 
AHR belongs to PAS (Per-ARNT-Sim) domain of the family of basic-helix-loop-
helix (bHLH) transcription factors [103]. AHR is sequestered in the cytoplasm as an 
inactive complex with a 90kDa heat shock protein (HSP90), XAP2 and p23 in absence of 
a ligand [101]. The prototypic ligand for AHR is 2,3,7,8-tetracholorodibenzo-p-dioxin (a 
by-product of industrial synthesis of herbicide) [101]. AHR signaling is tightly controlled 
by the chaperon proteins (HSP90, XAP2 and p23) and AHR nuclear translocator (ARNT). 
HSP90 helps mask the constitutive DNA binding affinity of AHR and maintains the 
receptor in a conformation that promotes high ligand binding affinity. XAP2 prevents 
ubiquitination of AHR prior to ligand binding and p23 prevents nuclear translocation of 
AHR complex and non-specific binding to ARNT in absence of bound ligand. Ligand 
binding causes conformational change in AHR complex (comprising AHR, three chaperon 
proteins and a ligand) that facilitates binding of importin β to the corresponding nuclear 
localization signal (NLS) which in turn promotes nuclear translocation of the complex. In 
the nucleus, ARNT binding to AHR complex induces dissociation of chaperon proteins 
and AHR-ARNT complex then binds to the corresponding DNA response elements in the 
promoter regions of their responsive genes that encode xenobiotic metabolizing enzymes 
such as CYP1A1 [101] (Figure 9). 
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Figure 9. Schematic representation of signal transduction pathway mediated by aryl hydro 
carbon receptor (AHR). 
 
 
 
 
 The main focus of this dissertation is to develop quantitative models that can 
predict dynamics of transcription factors and cytokines involved in signal transduction 
pathways triggered by bacterial components lipopolysaccharide (gram negative bacteria) 
and indole (derived from indigenous bacteria upon tryptophan metabolism and 
representing microbiota metabolism). The next chapter gives an overview of systems 
biology approach towards studying mammalian immune response and host-microbiota 
interactions by integrating experimental and mathematical techniques.  
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CHAPTER III 
SYSTEMS BIOLOGY APPROACH TOWARDS STUDYING MAMMALIAN 
IMMUNE RESPONSE 
3.1 MATHEMATICAL MODELING OF SIGNAL TRANSDUCTION 
PATHWAYS 
Systems biology is the quantitative study of biological interactions through 
integration of mathematical modeling and experimental measurements with the goal of 
being able to predict biological responses and outcomes. Model predictions and 
experimental measurements follow a cyclical loop where each is refined by the other 
(Figure 10). Model predictions can be used to design experiments whereas experimental 
data can validate and estimate model parameters  
Systems biology is a holistic study of biological systems as opposed to the 
reductionist approach and hence aims at studying a network of both extra- and intracellular 
interactions. Systems biology has evolved from the integration of complex biological 
interactions with simultaneous developments in high throughput technologies for data 
acquisition (e.g., genome sequencing, as shown in top line of Figure 11) and the 
identification of intricate networks in single and multi-cellular organisms (as shown in the 
bottom line of Figure 11).  
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Figure 10. Systems biology: integration of computational model predictions and 
experimental measurements. 
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Figure 11. History of systems biology [104]. 
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Cellular networks in biological systems can be broadly classified into three 
categories, namely, signal transduction pathways, metabolic networks and gene regulatory 
networks [105-107]. Signal transduction pathway refers to the steps involved in extra 
cellular stimulus initiating intracellular cascade of biochemical reactions 
(activation/deactivation of transcription factors) and altering cellular functions (through 
gene expression). Metabolic networks involve conversion of small biomolecules (that 
serve as carbon and nitrogen sources) to produce energy and intermediate products that 
are critical for cell survival and growth. Gene regulatory networks on the other hand deal 
with interaction of proteins (such as transcription factors) with DNA to induce gene 
expression. All three constitute integral parts of an organism and are highly interconnected 
to facilitate proper functioning of a cell. For example, energy derived from metabolic 
networks is essential to carry out signal transduction which in turn influences gene 
regulatory networks depending on the extracellular stimulus.  
Signal transduction is instantaneous and downstream effects are observed rapidly. 
For example cytoplasmic NF-κB gets activated within five minutes of extracellular 
stimulation [108]. Hence information about transient dynamics of activated proteins in 
signal transduction pathway is important to understand how the signaling pathway 
contributes to cellular responses. Elucidating signal transduction pathways involved in 
immune responses is non-trivial due to the sheer complexity and highly evolved 
interconnectivity between biomolecules. One extracellular stimulus can activate multiple 
signaling pathways; conversely, several extracellular molecules can activate the same 
signaling pathway as well. This complexity makes it extremely difficult to establish cause-
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and-effect relationships. Hence integration of mathematical modeling and experimental 
validation is needed to bridge the gap between what is already known and what needs to 
be known about signal transduction in highly complex organisms such as mammals.  
Several aspects of single signal transduction pathways have been fully understood 
till now because of the unavailability of experimental data or techniques to experimentally 
investigate certain biochemical reactions. However, computational models serve as a 
promising substitute for unexplored areas of experimental biology. Certain biochemical 
reactions in signal transduction pathways are so rapid that they are difficult to be 
monitored experimentally. However, computational models that can predict the nature of 
the reaction would be a good complement to experimental studies. Computational models 
are currently used in pharmaceutical industries to predict the feasibility of specific drugs 
or help select the right candidates for clinical trials, which eliminates the need for 
expensive experimental data.  
Though pro-inflammatory immune responses have been studied using 
computational models [31,107-109], no significant work has been done with respect to 
integrating pro- and anti-inflammatory responses which underlies homeostasis in our 
body. Mathematical modeling has attracted attention from systems biology researchers not 
only to help design experiments but also to predict their outcomes. Some of the common 
computational approaches to study biological systems are ordinary differential equations, 
Bayesian networks, Boolean networks and fuzzy logic [110]. Bayesian and Boolean 
networks are usually used to represent and predict steady state data for metabolic and gene 
regulatory networks [111]. However, ordinary differential equations are used in transiently 
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dynamic signal transduction models [31,112]. A good understanding of signal 
transduction pathways and quantitative predictions from model simulations can help study 
the feasibility of certain therapeutic molecules. This dissertation focuses at studying 
dynamic pro- and anti-inflammatory responses and how it might be regulated by host-
microbiota interactions using ordinary differential equation models.  
3.1.1 Ordinary differential equations (ODE) for component balance 
Dynamic profiles of components in a signal transduction pathway can be 
quantitatively predicted using non-linear ordinary differential equation (ODE) models. 
ODEs in such cases represent concentration balance for different components involved in 
the particular signaling pathway. The ODEs are usually of the form: 
𝑑𝑥
𝑑𝑡
= 𝑓(𝑥, 𝑢, 𝑝)              (3.1) 
where x is a vector of states (concentrations of biological components), u is a vector of 
inputs (stimulus) and p is a vector of parameters (reaction rate constants). 
The cell is considered a single batch reactor where biochemical reactions take place. 
Equation 3.1 represents the rate of change of the concentration of component ‘x’ at the 
rate ‘p’ under the effect of stimuli ‘u’. Component balance in signal transduction pathways 
are represented in two forms: 
 Mass action kinetics where the rate of change of a component depends on the 
rate of production and rate of consumption, as shown in equation (3.2) 
𝑑𝑥𝑖
𝑑𝑡
= ∑𝜈𝑖𝑝𝑟𝑜𝑑𝑢𝑐𝑒𝑑
−  ∑𝜈𝑖𝑐𝑜𝑛𝑠𝑢𝑚𝑒𝑑               (3.2) 
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Where, νi
produced
 and νi
consumed
 are the rates of component xi production and 
consumption respectively, following chemical kinetics of reactions it is involved 
with. Most of the biochemical reactions, for example, activation of transcription 
factor NF-κB under pro-inflammatory stimulus (as described in Chapter II) are 
represented in mass action kinetics form. 
 Michaelis-Menten kinetics is used to represent the process of gene expression 
(transcription) induced by transcription factor binding to the promoter region of 
the target gene. The enzyme kinetics of invertase as described in [113] is the basis 
for ODE models comprising mass action kinetics and Michaelis-Menten kinetics. 
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3.2 REVIEW OF SOME SIGNAL TRANSDUCTION AND HOST-MICROBIOTA 
INTERACTOME MODELS 
 A large number of databases are readily available online to refer to the different 
biochemical reactions taking place in physiological processes. Some popular databases 
are BioCarta (http://www.biocarta.com), BioCyc (www.biocyc.org), and KEGG 
(http://www.genome.jp/kegg/pathway.html). Mathematical models written in Systems 
Biology Makeup Language (SBML) are also available online for reference purposes 
(http://www.ebi.ac.uk/biomodels-main/). Among the pro-inflammatory transcription 
factors, TNF-α-induced activation of NF-κB is most widely studied and computationally 
modeled [31,32,108,112]. Lipniacki et al. [31], and Rangamani et al. [112], developed 
deterministic models comprising the cascade of intra-cellular biochemical reactions that 
are initiated by pro-inflammatory TNF-α signal. Moya et al. [114] developed a 
mathematical model that describes signal transduction pathways initiated by extracellular 
IL-6 (pro-inflammatory) and IL-10 (anti-inflammatory) signals, both targeted towards 
activation of transcription factor STAT3 in human hepatic cells. This was the first model 
that integrated pro- and anti-inflammatory responses in mammalian cells. 
 With the growing knowledge of intricate relationship shared by mammals and their 
intestinal microbiota, several experimental studies have been directed towards 
investigating complex host-microbiota interactions. Alteration in the intestinal microbiota 
population has been linked to the pathogenesis of intestinal bowel disease, obesity, and 
allergic reactions (as discussed in Chapter II). Several genome-scale metabolic models 
(GSMM) using big data sets have integrated knowledge of genes, reactions and metabolic 
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pathways in human intestinal microbiota and information about host and microbial 
metabolism and signaling to investigate metabolic pathways involved in digestion of 
polysaccharides and proteins in the gastro-intestinal tract by microbiota and in turn 
generation of small chain fatty acids such as acetate, propionate and butyrate [115,116]. 
Marino et al. [117] developed a mathematical model to study inter-population 
interactions among murine microbiota. Their model is based on co-relation analysis of 
data obtained from laboratory colonization of germ-free mice with cecal contents of a 
mature mouse. The model simulations predict a lack of mutualistic interactions with in a 
community of bacteria with significant parasitic interactions observed among the members 
of Bacteroidetes and competition among Firmicutes. Thus computational models based on 
metagenomics can elucidate interspecies interactions of intestinal microbiota that might 
have a potential contribution to host metabolism and transition from health to disease. 
Most of the computational models of studying host-microbiota interactions focus 
on metabolic pathways because of the availability of huge sets of metagenomic data and 
genome-scale metabolic models for some bacteria [118]. Research focused on studying 
the effect of intestinal microbiota on host immune responses (as discussed in Chapter II). 
Several host-pathogen computational models have been developed to study molecular 
mechanisms involved in the interactions between host and pathogenic micro-organisms 
while transitioning from health to disease in cases of HIV [119], malaria [120], 
tuberculosis [121] and influenza [122]. However, to our knowledge, no mathematical 
models have yet been developed to investigate the complex host-microbiota interactions 
that are essential in maintaining mucosal homeostasis (in the gastro-intestinal tract) and 
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alteration of which can lead to pathogenesis of inflammatory diseases. This is because the 
signal transduction pathways activated by bacterial metabolites in hosts are poorly 
understood. 
This dissertation focuses at investigating a possible molecular mechanism 
involved in host-microbiota interactions through indole-induced signaling and its effect 
on host immune responses and homeostasis. Immune homeostasis in host is essentially 
regulated by maintaining a balance between pro- and anti-inflammatory responses and 
their positive/negative feed-back regulatory loops. Chapter IV describes a mathematical 
model that is developed to study pro- and anti-inflammatory immune responses and feed-
back effects of host macrophages to maintain homeostasis under a continuous 
inflammatory signal from gram negative bacteria-derived lipopolysaccharide (LPS). 
Chapter V expands this by including for the first time signaling effects mediated by a 
bacterial metabolite indole. 
 47 
 
CHAPTER IV 
MATHEMATICAL MODELING OF PRO- AND ANTI-INFLAMMATORY 
IMMUNE RESPONSES IN MACROPHAGES2F 
4.1 OVERVIEW 
Inflammation is a beneficial mechanism that is usually triggered by injury or 
infection and is designed to return the body to homeostasis. However, uncontrolled or 
sustained inflammation can be deleterious and has been shown to be involved in the 
etiology of several diseases, including inflammatory bowel disorder and asthma. 
Therefore, effective anti-inflammatory signaling is important in the maintenance of 
homeostasis in the body. However, the inter-play between pro- and anti-inflammatory 
signaling is not fully understood. In the present study, we develop a mathematical model 
to describe integrated pro- and anti-inflammatory signaling in macrophages. The model 
incorporates the feedback effects of de novo synthesized pro-inflammatory (tumor 
necrosis factor α; TNF-α) and anti-inflammatory (interleukin-10; IL-10) cytokines on the 
activation of the transcription factor nuclear factor -κ B (NF-κB) under continuous 
lipopolysaccharide (LPS) stimulation (mimicking bacterial infection). In the model, IL-
10 upregulates its own production (positive feedback) and also downregulates TNF-α 
production through NF-κB (negative feedback). In addition, TNF-α upregulates its own 
                                                 
Reprinted with permission from “Mathematical modeling of pro- and anti-inflammatory signaling in 
macrophages” by Maiti, S.; Dai, W.; Alaniz, R.; Hahn, J.; Jayaraman, A., 2014. Processes, 3, 1-18, 
Copyright 2014 by MDPI. 
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production through NF-κB (positive feedback). Eight model parameters are selected for 
estimation involving sensitivity analysis and clustering techniques.  
We validate the mathematical model predictions by measuring phosphorylated 
NF-κB, de novo synthesized TNF-α and IL-10 in RAW 264.7 macrophages exposed to 
LPS. This integrated model represents a first step towards modeling the interactions 
between pro- and anti-inflammatory signaling. 
4.2 INTRODUCTION 
Inflammation is a beneficial self-defense mechanism that is initiated by the body 
to eliminate pathogens and prevent the spread of infection [123]. The inflammatory 
responses to pathogens and other inflammatory stimuli are mediated by innate (dendritic 
cells and macrophages) and adaptive immune cells (T-cells and B-cells) [124]. Immune 
cells have transmembrane receptors called Toll-like receptors (TLR) that recognize 
foreign molecules based on pathogen-associated molecular patterns (PAMPs), such as 
flagellin of bacterial flagella [39], lipopolysaccharide (LPS) of Gram-negative bacteria 
and peptidoglycan of Gram-positive bacteria [35]. Recognition of PAMPs by immune 
cells (such as macrophages) triggers the de novo synthesis and secretion of pro-
inflammatory cytokines, which leads to the recruitment of phagocytic cells, such as 
neutrophils [125], for eliminating pathogens. While inflammation is a beneficial body 
response, unabated (chronic) inflammation is deleterious, as it can result in immune cells 
attacking other host cells. Chronic inflammation has been shown to be involved in the 
etiology of several diseases, including inflammatory bowel disease (IBD) [126] and 
 49 
 
asthma [127]. Chronic inflammation can also arise in the absence of pathogen infection. 
Since the mucosal immune cells in the gastro-intestinal (GI) tract are in close proximity 
with intestinal microbiota [128], any alteration in the intestinal microbial community (i.e., 
dysbiosis) can also lead to uncontrolled pro-inflammatory responses. This sustained 
inflammation in the absence of any infection has been shown to result in ulcerative colitis 
or Crohn’s disease [126].  
Nuclear factor –κ B (NF-κB) is an important transcription factor that plays a 
pivotal role in mediating inflammatory responses in immune cells, such as macrophages 
[129]. NF-κB is made up of two subunits, p50 and p65 [130], and is sequestered as an 
inactive complex in the cytosol by an inhibitor protein, IκBα [129]. When macrophages 
detect the presence of bacteria (by recognizing LPS) through their cell surface receptor, 
TLR4, an LPS-TLR4 complex is formed that triggers the activation of IκBα kinase (IKK), 
resulting in phosphorylation of IκBα-NFκB and subsequent ubiquitination and 
degradation of IκBα [129]. NF-κB, which is catalytically released from the inactive IκBα-
NFκB complex, translocates into the nucleus and binds to response elements in the 
promoter region of its target genes to activate their transcription [129]. Several target 
genes with functions in inflammation and immune regulation have been identified for NF-
κB [131], of which TNF-α and IL-10 are the most prominent pro- and anti-inflammatory 
cytokines, respectively [132-134]. In addition to TNF-α and IL-10, other NF-κB 
responsive genes that have significant NF-κB regulatory functions are IκBα (sequesters 
free NF-κB) [135] and A20 (inactivates IKK) [136]. However, NF-κB is not the only 
transcription factor that regulates IL-10 and TNF-α signaling and often acts in concert 
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with other transcription factors. For example, signal transducer and activator of 
transcription 3 (STAT3) is a well-studied transcription factor involved in IL-10 signaling 
[137,138]. STAT3 not only regulates transcription of IL-10, but is itself activated by IL-
10 [139] and LPS [140] in a feedback manner. The effects of pro-inflammatory cytokines, 
such as TNF-α and IL-1, are countered by signaling initiated by anti-inflammatory 
cytokines. IL-10 is a potent anti-inflammatory cytokine and suppresses the production of 
pro-inflammatory cytokines, like TNF-α [141], by downregulating NF-κB through 
inhibition of IKK activation and suppression of free phosphorylated NF-κB translocation 
from cytosol to nucleus [142,143].  
Several computational models of inflammatory signaling have been previously 
developed. These include a model for the IL-6 signal transduction pathway by Singh et al. 
[144], the TNF-α signaling pathway by Huang et al. [32], Lipniacki et al. [31], Rangamani 
et al. [112] and Hoffmann et al. [108]. A characteristic feature of these models is that they 
describe the dynamics of signaling initiated by a single pro-inflammatory cytokine. Moya 
et al. [114] developed a mathematical model to represent interactions between IL-6 (pro-
inflammatory) and IL-10 (anti-inflammatory) in hepatocytes when both of these cytokines 
were used as stimuli to the cells. The current work describes an interplay between de novo 
synthesized pro-inflammatory (TNF-α) and anti-inflammatory (IL-10) cytokines in 
macrophages exposed to LPS (Figure 12). Since the inter-play between the pro- and anti-
inflammatory signaling in macrophages is poorly understood, our integrated model 
represents a first step towards modeling the interaction between pro- and anti-
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inflammatory signaling mediators that is important in inflammation and maintaining 
homeostasis.  
 
 
 
 
 
 
Figure 12. Schematic representation of LPS-induced signal transduction resulting in NF-
κB activation and de novo synthesis of TNF-α and IL-10 in macrophages. LPS-induced 
NF-κB activation is indicated in solid blue arrows. TNF-α-induced positive feedback 
regulation of NF-κB is indicated in dashed cyan arrows, and IL-10-induced negative 
feedback regulation of NF-κB is indicated in solid red lines. 
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4.3 MATERIAL AND METHODS 
4.3.1 Model formulation 
The mathematical model presented in this paper is an integration of an 
inflammatory module and an anti-inflammatory module. The model is developed by 
representing biochemical reactions involved in the signal transduction pathway as a set of 
non-linear ordinary differential equations (ODEs) of the form:  
𝑑𝑥
𝑑𝑡
= 𝑓(𝑥, 𝑢, 𝑝)               (4.1) 
where x is a vector of states, u is a vector of inputs and p is a vector of parameters in 
equation 4.1. The model comprises 29 differential equations and 37 parameters. Each 
differential equation represents the rate of change of the concentration of a particular 
protein involved in the pathway.  
The inflammatory (TNF-α) module is adapted from Huang et al. [32] and 
Lipniacki et al. [31]. While these models use TNF-α as the input, our model describes LPS 
(input)-induced signaling through TLR4 (LPS receptor), which leads to TNF-α 
production. Besides adding TLR4 to the model, the TNF-α receptor description is retained 
to represent the positive feedback of de novo synthesized TNF-α on NF-κB regulation. 
We have included a kinetic term for TNF-α mRNA transcription initiated by nuclear NF-
κB and component balances for TNF-α in the cytoplasm and the supernatant. In addition, 
Lipniacki et al., included TRADD, TRAF2, RIP-1, FADD, caspase-3 and caspase-8 
proteins, which are left out of the model presented here, as we focus mainly on some of 
the key biochemical reactions involved in LPS-induced NF-κB activation, its effect on the 
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production of TNF-α and IL-10 and in turn, the role of these cytokines on the feedback 
regulation of NF-κB. The similarities between the model described in Lipniacki et al. [31], 
and our current ODE model lie in the formulation of the biochemical reactions involved 
in IKK activation, IκBα-NFκB phosphorylation, dissociation and nuclear transport of NF-
κB, nuclear NF-κB-induced IκBα, A20 mRNA transcription, free NF-κB sequestration by 
de novo synthesized IκBα and IKK inactivation by A20. We added a balance for 
phosphorylated IκBα, as it is known to degrade after dissociation from the IκBα-NFκB 
complex.  
The anti-inflammatory (IL-10) module is adapted from the IL-6 and IL-10 model 
by Moya et al. [114]. Only the ODEs involved in IL-10 signaling through the IL-10 receptor 
(as mentioned in Moya et al. [114]) are included in the anti-inflammatory module of our 
current model to formulate the feedback effects of IL-10 on its own production (through 
positive feedback regulation of STAT3) and TNF-α production (through negative 
feedback regulation of NF-κB). Biochemical reactions, as described in Moya et al., for 
STAT3 phosphorylation, dimerization and nuclear translocation to initiate transcription 
are retained in our current model. Transcription and translation of SOCS3 due to STAT3 
and downstream biochemical reactions associated with SOCS3 are not included in the 
model presented here. A Michaelis–Menten-type kinetics for IL-10 transcription, initiated 
by the transcription factors, NF-κB and STAT3, and component balances for IL-10 in the 
cytoplasm and supernatant, have been included here. 
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Some values of the parameters and initial concentrations of proteins are adapted 
from the TNF-α signaling models by Huang et al. [32], Lipniacki et al. [31], Rangamani 
et al. [112], Hoffmann et al. [108] and the IL-6 and IL-10 model by Moya et al. [114]. 
The previously developed models consisted of 37 differential equations and 60 parameters 
for the TNF-α model by Huang et al. and 68 differential equations and 118 parameters for 
the IL-6 and IL-10 model by Moya et al. [114] Among the proteins included in these 
models, very few are quantifiable by experimental methods, making parameter estimation 
difficult. In our current integrated model, we have reduced the number of differential 
equations to 29 and the number of parameters to 37 by only focusing on the key proteins 
of the pathway. Using a smaller model increased parameter identifiability and simplified 
parameter estimation. 
The ODE model is structurally divided into pro-inflammatory (TNF-α) and anti-
inflammatory (IL-10) modules that are both initiated by LPS stimulation and NF-κB 
activation.  
Pro-Inflammatory Module: 
1. Exogenous LPS binds to the cell surface receptor (TLR4). 
2. LPS-TLR4 complex initiates activation of IKKneutral to IKKactive.  
3. IKKactive phosphorylates IκBα-NFκB and initiates dissociation of the inactive 
IκBα-NFκB complex into phosphorylated IκBα and NF-κB species.  
4. Free phosphorylated IκBα undergoes ubiquitination and degradation, whereas free 
cytoplasmic NF-κB translocates into nucleus. 
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5. Nuclear NF-κB binds to response elements in the promoter regions of TNF-α, IκBα 
and A20 genes and leads to transcription and translation of the corresponding 
proteins and subsequent secretion of TNF-α into the supernatant. de novo 
intracellular IκBα sequesters both free cytoplasmic and nuclear NF-κB by binding 
to them, and A20 catalyzes the change of IKKactive to the IKKinactive form. 
6. Secreted TNF-α in the cell culture supernatant binds to its cell surface receptor to 
form a complex that initiates similar pathways as LPS, resulting in the production 
of more TNF-α through a positive feedback regulation on NF-κB. 
Anti-Inflammatory Module: 
1. Nuclear NF-κB binds to the IL-10 gene promoter and initiates transcription of IL-
10 mRNA and subsequent translation into IL-10 protein in the cytoplasm, which 
gets secreted into the supernatant. 
2. IL-10 secreted into the supernatant binds to its cell surface receptor, forming a 
ligand-receptor complex that inhibits activation of IKKneutral to IKKactive and 
translocation of activated free cytoplasmic NF-κB into the nucleus as well. 
3. The IL-10 + receptor complex activates a second transcription factor, presumably 
STAT3, which, in turn, regulates transcription of the IL-10 gene in a feed-forward 
manner. 
Below is the schematic representation of the implemented reaction network (Figure 13). 
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Figure 13. Implemented reaction network for LPS-induced NF-κB signal transduction 
pathway with TNF-α (positive) and IL-10 (negative) feedback regulations. 
 
 
 
 
Different LPS concentrations (0, 0.1, 1, 10 μg/mL) are used to stimulate the model. 
The IKK complex and NF-κB dimer (p50–p65) are considered as single proteins in the 
model. The signal transduction model comprises feedback regulatory loops involving 
TNF-α and IL-10. The positive feedback of TNF-α on its own production is represented 
by de novo TNF-α binding to its cell surface receptor, activating IKKneutral to IKKactive, 
leading to phosphorylation and dissociation of the IκBα-NFκB complex to release NF-κB, 
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which translocates to the nucleus to initiate transcription of TNF-α. IL-10 has a negative 
feedback effect on TNF-α production by inhibiting NF-κB activation (phosphorylation 
and dissociation), and the extent of this inhibition is calculated on the basis of the ligand 
bound IL-10 receptor complex (IL10-IL10R) concentration, which is represented as kin as 
shown in equation 4.2. 
 
kin = max [(1 −
[IL10−IL10R]
[IL10−IL10Rmax]
),0]                                                              (4.2) 
 
The maximum attainable concentration of IL10-IL10R is denoted by IL10-
IL10Rmax with an assumed value of 2.56 × 10
−6. kin is multiplied to factors that are 
inhibited by IL-10, such as IKK activation and nuclear translocation of free cytoplasmic 
NF-κB [142,143]. The higher the concentration of the IL10-IL10R complex, the lower 
will be the value of kin and, hence, the lower will be the contribution of the terms 
mentioned above to the total outcome of NF-κB signaling, resulting in suppression of 
TNF-α production by IL-10. Positive feedback of IL-10 on its own production is 
represented by a set of differential equations that describe the IL-10 bound receptor 
complex phosphorylating transcription factor STAT3, which then dimerizes and 
translocates into the nucleus, binds to the promoter region of the IL-10 gene and initiates 
transcription of IL-10 mRNA and subsequent translation and secretion of IL-10 protein. 
The differential equations used in formulating the current model and the initial 
concentrations of the state variables (different components of the model) are shown in 
Table 1 and Table 2.  
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Table 1. Differential equations representing biochemical reactions involved in LPS-induced 
NF-κB signal transduction pathway, as used in the pro- and anti-inflammatory ODE 
model.  
 
1. 
d[TLR4]
dt
= −𝑘𝑓1 × [LPS][TLR4] + 𝑘𝑟1 × [LPS − TLR4] 
2. 
d[LPS−TLR4]
dt
= 𝑘𝑓1 × [LPS][TLR4] − 𝑘𝑟1 × [LPS − TLR4] 
3. 
d[IL−10sup]
dt
= −𝑘𝑓2 × [IL − 10sup][IL − 10R] + 𝑘𝑟2 × [IL10 − IL10R] + 𝑘𝑠𝑒𝑐𝐼𝐿10 × [IL −
10cyto] ×
0.36
200
− 𝑘𝑑𝑒𝑔𝐼𝐿−10𝑠𝑢𝑝 × [IL − 10sup] 
4. 
d[IL−10R]
dt
= −𝑘𝑓2 × [IL − 10][IL − 10R] + 𝑘𝑟2 × [IL10 − IL10R] 
5. 
d[IL10−IL10R]
dt
= 𝑘𝑓2 × [IL − 10sup][IL − 10R] − 𝑘𝑟2 × [IL10 − IL10R] 
6. 
d[TNF−αsup]
dt
= −𝑘𝑓3 × [TNF − αsup][TNF − αR] + 𝑘𝑟3 × [TNFα − TNFαR] + 𝑘𝑠𝑒𝑐𝑇𝑁𝐹𝛼 × [TNF −
αcyto] ×
0.36
200
− 𝑘𝑑𝑒𝑔𝑇𝑁𝐹𝛼𝑠𝑢𝑝 × [TNF − αsup] 
7. 
d[TNF−αR]
dt
= −𝑘𝑓3 × [TNF − αsup ][TNF − αR] + 𝑘𝑟3 × [TNFα − TNFαR] 
8. 
d[TNFα−TNFαR]
dt
= 𝑘𝑓3 × [TNF − αsup ][TNF − αR] − 𝑘𝑟3 × [TNFα − TNFαR] 
9. 
d[IKKn]
dt
= −𝑘𝑓𝑖 × 𝑘𝑖𝑛 × ([LPS − TLR4] + [TNFα − TNFαR]) × [IKKn] + 𝑡𝑖3 × [IKKa −
I𝜅BαNF𝜅Bcyto] 
where, kin = max [(1 −
[IL10−IL10R]
[IL10−IL10Rmax]
),0] 
10. 
d[IKKa]
dt
= 𝑘𝑓𝑖 × 𝑘𝑖𝑛 × ([LPS − TLR4] + [TNFα − TNFαR]) × [IKKn] − 𝑘𝑘3 × 𝑘𝑖𝑛 × [IKKa] ×
[I𝜅Bα − NF𝜅Bcyto] − 𝑘𝑘1 × [IKKa] × [A20cyto] 
11. 
d[IKKi]
dt
= 𝑘𝑘1 × [IKKa] × [A20cyto] 
12. 
d[I𝜅Bα−NF𝜅Bcyto]
dt
= 𝑘𝑓4 × [NF𝜅Bcyto][I𝜅Bαcyto] + 𝑒𝑛𝑖 × [I𝜅Bα − NF𝜅Bnuclear] × 𝑘𝑣 − 𝑘𝑘3 × 𝑘𝑖𝑛 ×
[IKKa] × [I𝜅Bα − NF𝜅Bcyto] 
13. 
d[IKKa−I𝜅BαNF𝜅Bcyto]
dt
= 𝑘𝑘3 × 𝑘𝑖𝑛 × [IKKa] × [I𝜅Bα − NF𝜅Bcyto] − 𝑡𝑖3 × [IKKa − I𝜅BαNF𝜅Bcyto] 
14. 
d[NF𝜅Bcyto]
dt
= −𝑘𝑓4 × [NF𝜅Bcyto][I𝜅Bαcyto] + 𝑡𝑖3 × [IKKa − I𝜅BαNF𝜅Bcyto] − 𝑖𝑙𝑛 × 𝑘𝑖𝑛 ×
[NF𝜅Bcyto] 
15. 
d[NF𝜅Bnuclear]
dt
= 𝑖𝑙𝑛 × 𝑘𝑖𝑛 ×
[NF𝜅Bcyto]
kv
− 𝑘𝑓4 × [NF𝜅Bnuclear][I𝜅Bαnuclear] 
16. 
d[I𝜅Bαphopsho]
dt
= 𝑡𝑖3 × [IKKa − I𝜅BαNF𝜅Bcyto] − 𝑘𝑑𝑒𝑔𝐼𝜅𝐵𝛼 × [I𝜅Bαcyto] 
17. 
d[A20mRNA]
dt
= 𝑆𝑚 × 𝑝 ×
[NF𝜅Bnuclear]
C+[NF𝜅Bnuclear]
− 𝐷𝑚 × [A20mRNA] 
18. 
d[A20cyto]
dt
= 𝑎20𝑡𝑟𝑎𝑛𝑠 × [A20mRNA] − 𝑘𝑑𝑒𝑔𝐴20 × [A20cyto] 
19. 
d[I𝜅BαmRNA]
dt
= 𝑆𝑚 × 𝑝 ×
[NF𝜅Bnuclear]
C+[NF𝜅Bnuclear]
− 𝐷𝑚 × [I𝜅BαmRNA] 
20. 
d[I𝜅Bαcyto]
dt
= −𝑘𝑓4 × [NF𝜅Bcyto][I𝜅Bαcyto] + 𝑖𝜅𝑏𝛼𝑡𝑟𝑎𝑛𝑠 × [I𝜅BαmRNA] − 𝑖𝑘𝑖 × [I𝜅Bαcyto] + 𝑒𝑘𝑖 ×
[I𝜅Bαnuclear] × 𝑘𝑣 
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Table 1. Continued. 
 
21. 
d[I𝜅Bαnuclear]
dt
= −𝑘𝑓4 × [NF𝜅Bnuclear][I𝜅Bαnuclear] + 𝑖𝑘𝑖 ×
[I𝜅Bαcyto]
kv
− 𝑒𝑘𝑖 × [IkBαnuclear] 
22. 
d[I𝜅Bα−NF𝜅Bnuclear]
dt
= 𝑘𝑓4 × [NF𝜅Bnuclear][I𝜅Bαnuclear] − 𝑒𝑛𝑖 × [I𝜅Bα − NF𝜅Bnuclear] 
23. 
d[IL−10mRNA]
dt
= 0.4 × 𝑆𝑚 × 𝑝 ×
[NF𝜅Bnuclear]
C+[NF𝜅Bnuclear]
 + 0.6 × 𝑆𝑚_𝑖𝑙10 × 𝑝 ×
[STAT3nuclear]
C_STAT3+[STAT3nuclear]
−
𝐷𝑚 × [IL − 10mRNA] 
24. 
d[IL−10cyto]
dt
= 𝑖𝑙10𝑡𝑟𝑎𝑛𝑠 × [IL − 10mRNA] − 𝑘𝑠𝑒𝑐𝐼𝐿10 × [IL − 10cyto] − 𝐷𝑛 × [IL − 10cyto] 
25. 
d[TNF−αmRNA]
dt
= 𝑆𝑚 × 𝑝 ×
[NF𝜅Bnuclear]
C+[NF𝜅Bnuclear]
− 𝐷𝑚 × [TNF − αmRNA] 
26. 
d[TNF−αcyto]
dt
= 𝑡𝑛𝑓𝛼𝑡𝑟𝑎𝑛𝑠 × [TNF − αmRNA] − 𝑘𝑠𝑒𝑐𝑇𝑁𝐹𝛼 × [TNF − αcyto] − 𝐷𝑛 × [TNF − αcyto] 
27. 
d[STAT3cyto]
dt
= −2 × 𝑘1 × [IL10 − IL10R][STAT3cyto]
2 + 2 × 𝑘2 × [STAT3 − STAT3cyto] 
28. 
d[STAT3−STAT3cyto]
dt
= 𝑘1 × [IL10 − IL10R][STAT3cyto]
2 − 𝑘2 × [STAT3 − STAT3cyto] − 𝑖𝑠𝑡𝑎𝑡3 ×
[STAT3 − STAT3cyto] + 𝑒𝑛𝑖 × [STAT3 − STAT3nuclear] × 𝑘𝑣 
29. 
d[STAT3−STAT3nuclear]
dt
= 𝑖𝑠𝑡𝑎𝑡3 ×
[STAT3−STAT3cyto]
kv
− 𝑒𝑛𝑖 × [STAT3 − STAT3nuclear] 
 
 
 
 
Table 2. State variables and their initial values as used in the pro- and anti-inflammatory 
ODE model. 
 
 
Sr. No. 
 
 
State variables 
 
Initial values, µM 
1. TLR4 1.0 × 10−1  
2. LPS-TLR4 0 
3. IL-10supernatant 4.6 × 10−6 
4. IL-10R 1.0 × 10−1 
5. IL10-IL10R 0 
6. TNF-αsupernatant 0 
7. TNF-αR 1.0 × 10−1 
8. TNFα-TNFαR 0 
9. IKKneutral 2.0 × 10−1 
10. IKKactive 0 
11. IKKinactive 0 
12. IκBα-NFκBcyto 2.5 × 10−1 
13. IKK- IκBαNFκB 0 
14. NFκBcyto 3.0 × 10−3 
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Table 2. Continued. 
 
 
Sr. No. 
 
 
State variables 
 
Initial values, µM 
15. NFκBnuclear 0 
16. IκBαphopsho 0 
17. A20mRNA 0 
18. A20cyto 4.8 × 10−3 
19. IκBαmRNA 0 
20. IκBαcyto 2.5 × 10−3 
21. IκBαnuclear 0 
22. IκBα-NFκBnuclear 0 
23. IL-10mRNA 0 
24. IL-10cyto 0 
25. TNF-αmRNA 0 
26. TNF-αcyto 0 
27. STAT3cyto 5.92 × 10−1 
28. STAT3-STAT3cyto 0 
29. STAT3-STAT3nuclear 0 
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4.3.2 Parameter selection and estimation 
The parameter estimation problem for a dynamic system described by ordinary 
differential equations (ODEs) can be mathematically formulated as follows:  
 
where yik and ŷik are the simulated and measured output data of the i-th component at 
sampling time tk, respectively, as shown in equation (4.3); p are the parameters to be 
estimated, which are selected by local sensitivity analysis; x are the state variables of the 
dynamic system with initial values x0; and u are the inputs to the system in equation (4.4). 
The output y is a function of x, as shown in equation (4.5). In addition, the state variables x 
and parameters p are restricted within certain ranges, as shown in equations (4.6) and (4.7), 
determined by the underlying biology and prior knowledge based on mathematical models 
developed by Lipniacki et al. [31], Huang et al. [32] and Rangamani et al. [112]. 
In this study, the simulated output vector y in equation (4.5), which is validated by 
experimental data, includes the intracellular ratio of phosphorylated NF-κB to total NF-
κB (relative to the control) and the concentration of the cytokines, TNF-α and IL-10, in 
min
𝑝
∑ ∑ 𝑤𝑖𝑘(𝑦𝑖𝑘 − ?̂?𝑖𝑘)
2
𝑘𝑖
 (4.3) 
Subject to, ?̇?(𝑡) = 𝑓(𝑥, 𝑢, 𝑝), 𝑥(0) = 𝑥0 (4.4) 
𝑦 = 𝑔(𝑥) (4.5) 
𝑥𝑙𝑏 ≤ 𝑥 ≤ 𝑥𝑢𝑏 (4.6) 
𝑝𝑙𝑏 ≤ 𝑝 ≤ 𝑝𝑢𝑏 (4.7) 
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the cell culture supernatant. Since the experiments are conducted with four different levels 
of the input u (i.e., different concentrations of LPS, 0, 0.1, 1 and 10 µg/mL), four sets of 
measured outputs ŷik are obtained. Three sets of data obtained for 0, 0.1 and 1 µg/mL LPS 
stimulations are used for parameter estimation, and the fourth dataset for 10 µg/mL LPS 
stimulation is used for model validation.  
First, the set of parameters that are to be estimated are selected by local sensitivity 
analysis and hierarchical clustering. Following this, the trust-region optimization 
technique is used to estimate the selected parameters. This technique is used in this work, 
as it is able to handle singular Hessian matrices, significant uncertainty in the parameters 
of the models and noisy data. In this technique, an optimization algorithm is applied in an 
outer loop, while the evaluation of the objective function and its gradients are performed 
by numerical integration of the ODEs in the inner loop [145,146] (shown in Figure 14). 
The trust-region method is guaranteed to converge to local optima with much weaker 
assumptions than line search methods. In this work, fmincon (MATLAB function) is used as 
the NLP (non-linear programming) solver and ode15s (MATLAB function) is used as the 
ODE integrator. It is worth noting that ode15s is specifically designed for stiff systems, 
such as the model discussed here, where both fast and slow dynamics exist, e.g., in our 
system, phosphorylation of NF-κB is a much faster process than de novo synthesis of TNF-
α and IL-10. Values of the parameters used in the model and initial concentrations of 
proteins are shown in Table 3. 
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Figure 14. Algorithm for parameter estimation used to optimize pro- and anti-
inflammatory ODE model parameters.  
 
 
 
 
Table 3. List of parameters used in the pro- and anti-inflammatory ODE model. 
Estimated parameters are indicated in boldface. 
 
 
Sr. No. 
 
Parameter Description Value Units Comment 
1. kv Nuclear: Cytoplasmic (Volume) 1.17 NA Estimated 
2. kf1 LPS binding to receptor 
2.64 × 
10−1 
(µM−s)−1 Estimated 
3. kr1 
Dissociation of LPS + receptor 
complex 
1.25 × 
10−3 
(µM−s)−1 Huang et al. (2008) [32] 
4. kf2 IL-10 binding to receptor 
2.50 × 
10−4 
(µM−s)−1 Assumed 
5. kr2 
Dissociation of IL-10 + receptor 
complex 
6.11 × 
10−4  
(µM−s)−1 Assumed 
6. kf3 TNF-α binding to receptor 
2.50 × 
10−3  
(µM−s)−1 Gray et al. [147] 
7. kr3 
Dissociation of TNF-α + receptor 
complex 
1.25 × 
10−3  
(µM−s)−1 
Rangamani et al. (2007) 
[112] 
8. kf4 IκBa and NF-κB association 2.5 × 10−3 (µM−s)−1 Assumed 
9. kfi IKK activation 
1.62 × 
10−3  
s−1 Estimated 
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Table 3. Continued. 
 
 
Sr. No. 
 
Parameter Description Value Units Comment 
10. kk1 Inactivation of IKK by A20 2.5 × 10−4  (µM-s)−1 Assumed 
11. kk3 Association of IKK with IκBα-NFκB 1.0 (µM−s)−1 
Lipniacki et al. (2004) 
[31] 
12. ti3 
Catalytic breakdown of IKK-IκBα-
NFκB 
1.72 × 
10−4  
s−1 Estimated 
13. iln NF-κB nuclear import 
1.52 × 
10−3 
s−1 Estimated 
14. a20trans A20 translation 
5.00 × 
10−1 
s−1 
Lipniacki et al. (2004) 
[31] 
15. kdegA20 Degradation of A20 protein 
3.00 × 
10−4 
s−1 
Lipniacki et al. (2004) 
[31] 
16. iκbαtrans IκBα translation 
5.00 × 
10−1 
s−1 
Lipniacki et al. (2004) 
[31] 
17. kdegIκBα Degradation of phosphorylated IκBα 
1.28 × 
10−4 
s−1 
Assumed half-life of 90 
min 
18. il10trans IL-10 translation 
5.00 × 
10−1 
s−1 
Lipniacki et al. (2004) 
[31] 
19. ksecIL10 
Secretion of IL-10 from cytoplasm to 
supernatant 
2.03 × 
10−5 
s−1 Assumed 
20. kdegIL10sup Degradation of IL-10 in supernatant 
7.40 × 
10−5 
s−1 
Half-life of 2.6 h in 
supernatant. Fedorak et al. 
[148] 
21. tnfαtrans TNF-α translation 
5.00 × 
10−1 
s−1 
Lipniacki et al. (2004) 
[31] 
22. ksecTNFα 
Secretion of TNF-α from cytoplasm 
to supernatant 
5.16 × 
10−5 
s−1 Estimated 
23. kdegTNFαsup 
Degradation of TNF-α in 
supernatant 
7.46 × 
10−5 
s−1 Estimated 
24. Dn Degradation of intracellular cytokine 
1.04 × 
10−2 
s−1 Huang et al. (2008) [32] 
25. iki IκBα nuclear import 
1.00 × 
10−3 
s−1 
Lipniacki et al. (2004) 
[31] 
26. eki IκBα nuclear export 
5.00 × 
10−4 
s−1 
Lipniacki et al. (2004) 
[31] 
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Table 3. Continued. 
 
 
Sr. No. 
 
Parameter Description Value Units Comment 
27. eni IκBα -NFκB nuclear export 
1.00 × 
10−2 
s−1 
Lipniacki et al. (2004) 
[31] 
28. k1 STAT3 activation and dimerization 
1.54 × 
10−2  
(µM−s)−1 Assumed 
29. k2 Dissociation of STAT3 dimer 3.3 × 10−5 s−1 Assumed 
30. istat3 STAT3 dimer nuclear import 
3.56 × 
10−5 
s−1 Estimated 
31. Sm Transcription due to NF-κB 
1.00 × 
10−1 
s−1 Huang et al. (2008) [32] 
32. Sm_il10 IL-10 Translation due to STAT3 1.5 s−1 Assumed 
33. p Transcription parameter 
5.00 × 
10−3 
µM Huang et al. (2008) [32] 
34. Dm Degradation of mRNA 
1.04 × 
10−2 
s−1 Huang et al. (2008) [32] 
35. C 
Maximum NF-κB concentration in 
nucleus 
1.08 × 
10−1 
µM Huang et al. (2008) [32] 
36. CSTAT3 
Maximum STAT3 concentration in 
nucleus 
5.00 × 
10−2 
µM Assumed 
37. IL10-IL10Rmax IL10-IL10R maximum concentration 
2.56 × 
10−6 
µM Assumed 
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4.3.3 Cell culture and experimental set-up 
The murine macrophage cell line RAW264.7 which is derived from ascites (American 
Type Culture Collection, Manassas, VA) was routinely cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) with 10% FBS (heat inactivated at 56ᵒC for 30 minutes), 100 
U/ml penicillin and 100 µg/ml streptomycin. LPS (heat-killed Salmonella enterica) was 
purchased from Sigma Aldrich (St. Louis, MO, USA). 
4.3.3.1. LPS stimulation of macrophages 
RAW264.7 cells were seeded at a density of ~2.0 × 105 cells/well in a 96-well 
tissue culture plate and allowed to attach overnight. Cells were stimulated with different 
concentrations (0, 0.1, 1and 10 μg/mL) of LPS diluted in growth medium. Whole cells 
were used to measure total and phosphorylated NF-κB after 5, 15, 30, 45, 60, 120 and 240 
minutes post-LPS stimulation. Culture supernatants were collected after 2, 4, 8, 12, 16, 20 
and 24 hours post-LPS stimulation to measure secreted TNF-α and IL-10 concentrations.  
4.3.3.2. Transcription factor NF-κB quantification by ELISA  
The relative concentrations of total and phosphorylated NF-κB in LPS-stimulated 
RAW264.7 macrophage cells were determined using a commercially-available enzyme-
linked-immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) 
according to the manufacturer’s suggested protocol. 
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4.3.3.3 Cytokines TNF-α and IL-10 quantification by ELISA 
The concentrations of de novo synthesized TNF-α and IL-10 in LPS-stimulated 
RAW264.7 macrophage culture supernatant were determined by commercially available 
enzyme-linked immunosorbent assay (ELISA) kits (Thermo Scientific, Rockford, IL, 
USA), using the manufacturer’s suggested protocol. 
4.4 RESULTS AND DISCUSSION 
Based on published reports of LPS stimulation resulting in TNF-α [149] and IL-
10 secretion [150] in RAW264.7 murine macrophages, as well as the established 
suppression of TNF-α by IL-10 in RAW264.7 cells [149], we developed an integrated 
ODE model to represent the production of TNF-α and IL-10 in RAW264.7 cells upon LPS 
stimulation and their regulatory feedback loops. Eight parameters of the model are 
selected for estimation using local sensitivity analysis and hierarchical clustering (shown 
in Figure 15) [151,152]. The y-axis represents the parameter distance ranging from zero 
to one (the larger the distance, the smaller the similarity between the parameters). The red 
line presents the cutoff value, which groups the entire set of parameters into eight pairwise 
indistinguishable clusters. The normalized sensitivity magnitudes of the parameters are 
reflected in the histograms. The values of the selected parameters are estimated using the 
trust-region optimization technique and the advantage of this approach is that the selected 
parameters used for estimation result in a more robust dynamic model with an accurate 
prediction capability [152]. 
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Figure 15. Representation of local sensitivity analysis results used for selecting pro- and 
anti-inflammatory ODE model parameters that are to be estimated. The y-axis represents 
the parameter distance ranging from zero to one (the larger the distance, the smaller the 
similarity between the parameters). The red line presents the cutoff value, which groups 
the entire set of parameters into eight pairwise indistinguishable clusters. The selected 
parameters, which have the largest sensitivity magnitude in each cluster, are highlighted 
in red. The normalized sensitivity magnitudes of the parameters are reflected in the 
histograms. 
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Model simulations after parameter estimation predict rapid phosphorylation of NF-
κB upon exposure to LPS, as shown in Figure 16 (A). The maximum fold change in the 
ratio of phosphorylated NF-κB to total NF-κB in LPS-treated cells relative to control 
increased with increasing LPS concentration and varied from ~2.0 at the highest LPS 
concentration to being essentially unchanged at the lowest concentration as shown in 
Figure 16 (A).  
Simulation of de novo synthesized TNF-α profile upon LPS stimulation shows that 
the TNF- concentration reaches a maximum of ~1500 pg/mL at 4 hours and starts 
declining thereafter. Even though LPS is continuously present, TNF-α is undetectable at 
24 hours for all LPS concentrations as shown in Figure 16 (B). The maximum TNF-α 
concentration at 4 hours increases with increasing concentrations of LPS. According to 
the model predictions, the de novo synthesized IL-10 concentration increases beyond 2 
hours of LPS stimulation, as shown in Figure 16 (C), and the concentration of IL-10 
produced increases with increasing LPS concentrations. 
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(A) 
 
Figure 16. Comparison of model predictions and experimental data for LPS-
stimulated RAW264.7 macrophages. (A) Profile of phosphorylated NF-κB/Total NF-
κB in LPS-treated macrophages relative to the control; (B) Profile of de novo 
synthesized TNF-α (pg/mL) upon LPS stimulation; (C) Profile of de novo synthesized 
IL-10 (pg/mL) upon LPS stimulation. 
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(B) 
 
(C) 
 
Figure 16. Continued. 
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 Model simulations are validated by experimental data obtained from LPS-
stimulated RAW264.7 cells. The comparison between simulated and experimental data 
for the fold change in NF-κB (phosphorylated NF-κB/Total NF-κB, relative to control), 
de novo TNF-α and IL-10 concentration profiles after parameter estimation are shown in 
Figures 16 (A), 16 (B) and 16 (C), respectively. In Figure 16 (A), the discrepancy between 
the model simulation and experimental data for 0.1 µg/mL LPS stimulation could arise 
from our assumption that the binding affinity between LPS and TLR4 is constant and 
concentrations of the LPS-TLR4 complex are linearly proportional to the concentrations 
of LPS tested. However, in reality, the ligand-receptor binding kinetics might follow a 
non-linear behavior, which is not accommodated in our computational model. The binding 
of LPS to TLR4 even at lower concentrations of LPS (e.g., 0.1 µg/mL) might result in 
higher concentrations of the LPS-TLR4 complex, resulting in more downstream 
phosphorylation of NF-κB (as indicated by the higher phosphorylated NF-κB/total NF-κB 
ratio for the experimental data in Figure 16 (A) than the model is able to predict. However, 
the dynamic model where the parameters have been estimated exhibits a reasonably good 
fit for phosphorylated NF-κB/total NF-κB profiles (relative to control) at 0 μg/mL, 1 
μg/mL and 10 μg/mL LPS stimulations. Furthermore, the model exhibits reasonable 
agreement between simulated and experimental data for both training and validation 
datasets for the TNF-α and IL-10 dynamic concentration profiles. 
 The model suggests that the initial increases in TNF-α and IL-10 are due to NF-
κB activation (i.e., phosphorylation and dissociation of NF-κB from IκBα-NF-κB 
complex) in the cytoplasm and subsequent gene expression in the nucleus; and the 
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decrease in TNF-α concentration after 4 hour is due to the negative feedback of IL-10 on 
NF-κB activity (by inhibiting both IKK activation and nuclear translocation of 
phosphorylated NF-κB). Interestingly, the levels of IL-10 continue to increase, even when 
the levels of activated NF-κB are no longer increasing. It is possible that the initial burst 
of IL-10 produced through NF-κB activation can activate other transcription factors, 
which leads to an increase in IL-10 levels. An example of this could be the transcription 
factor STAT3, which has been shown to be activated by IL-10 [153]. Endogenous IL-10 
in LPS stimulation of macrophages (RAW264.7) [154] forms the IL-10-IL10R complex 
that initiates phosphorylation of cytosolic STAT3, followed by its dimerization and 
translocation into the nucleus. The STAT3 dimer binds to the DNA response element and 
triggers transcription of IL-10 (Figure 17). Thus, increasing LPS concentration could lead 
to increasing concentrations of IL-10 due to the positive feedback of IL-10 on its own 
production. 
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Figure 17. Schematic representation of STAT3 activation under LPS-induced de novo 
IL-10 production and feed-forward regulation in macrophages. 
 
 
 
 
It can be seen that the model predictions and experimental data are in reasonable 
agreement, which demonstrates that biochemical reactions, which form the structure of 
the model, are physiologically relevant and can depict the interplay between pro-
inflammatory and anti-inflammatory immune responses to maintain equilibrium 
(homeostasis). Furthermore, cross-talk between positive and negative feedback regulatory 
loops, incorporated in the model, is integral towards mathematically representing 
biochemical and gene regulatory networks, as mentioned by Tian et al. [155]. Our model 
also shows that the anti-inflammatory functions in the RAW264.7 macrophage cell line is 
initially triggered by pro-inflammatory stimulation. This model structure can be extended 
 75 
 
to study other cell types with a modification in parameter values to fit model predictions 
to experimental datasets for specific cell types.  
The integrated mathematical model of pro- and anti-inflammatory host immune 
response discussed in this chapter is a step towards assimilating our knowledge and 
developing a quantitative understanding of the signal transduction pathways involved in 
maintaining immune homeostasis, disruption of which can lead to inflammatory disorders. 
This mathematical model can be further used to study intra- and inter-kingdom signaling, 
i.e., the effect of bacterial metabolites (e.g., indole) synthesized by micro flora present in 
the host gastro-intestinal tract on host immune response [29]. This model can be used as 
the basic structure to incorporate additional transcription factors, which will be needed to 
study the signaling of indole and their interactions with NF-κB, as described in Chapter 
V. 
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CHAPTER V 
INTEGRATED INTRA- AND INTER-KINGDOM SIGNALING OF 
INFLAMMATORY RESPONSES  
5.1 OVERVIEW 
 Inter-kingdom signaling in mammals arises from the complex interactions that take 
place between the mammalian hosts and indigenous bacteria (microbiota) residing in 
them. The microbiota is highly diverse in species and functions, ranging from indifferent 
commensal bacteria and beneficial mutualistic bacteria to disease causing pathobionts. It 
has been reported that the beneficial bacteria help in maintaining homeostasis in the host 
by modulating host immune responses against exogenous pathogenic and potentially 
harmful indigenous bacteria. However, the signal transduction induced by these beneficial 
bacteria in hosts and the molecular mechanisms involved in influencing host immune 
responses are not well understood. In this chapter we investigate a potential bacterial 
metabolite, indole-induced signaling in hosts that results in immunomodulation.  
We studied indole-induced signal transduction pathway through activation of aryl 
hydrocarbon receptor (AHR) in down regulating nuclear factor- κ B (NF-κB) activation 
and inhibition of subsequent interleukin 8 (IL-8) production, by integrating mathematical 
modeling and experimental techniques. We observed that indole treatment at a 
concentration of 1 mM under moderately low pro-inflammatory stimuli (i.e., 0.1 and 1 
ng/mL TNF-α) significantly down-regulates NF-κB activation and IL-8 synthesis whereas 
under 10 ng/mL TNF-α stimulation, inhibition of IL-8 lasts for only 4 hours post-
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stimulation and down regulation of NF-κB activation is not statistically significant. 0.5 
mM indole shows no significant NF-κB down regulation under any TNF-α concentrations 
but exhibits IL-8 inhibition for 12 hours post-TNF-α stimulation at 0.1 ng/mL and for 4 
hours post-TNF-α stimulations at 1 and 10 ng/mL. 0.25 mM indole treatment on the other 
hand shows no significant down regulation of NF-κB under any concentration of TNF-α 
stimulus but exhibits IL-8 synthesis for 12 hours post-TNF-α stimulation at 0.1 ng/mL and 
for 4 and 2 hours post-TNF-α stimulations at 1 and 10 ng/mL respectively. 
5.2 INTRODUCTION 
Cross-talk between host and approximately 1014 indigenous bacterial cells 
belonging to ~1000 strains, inhabiting the gastro-intestinal (GI) tract in close proximity to 
host cells [10] is speculated to give rise to a complex network of inter-kingdom signaling 
between host and microbiota. Beneficial intestinal bacteria present in the mucous layer of 
the gastro-intestinal (GI) tract modulate mucosal immunity to prevent pathogenic 
exogenous and potentially harmful indigenous bacteria from colonizing the GI tract [13]. 
In this work we investigate intestinal bacteria-derived metabolite indole as a potential 
inter-kingdom signaling molecule.  
Indole is a derivative of tryptophan (amino acid) which is produced by bacterial 
metabolism of tryptophan using enzyme tryptophanase A (encoded by tnaA in Escherichia 
coli). Escherichia coli also possesses tnaB that encodes for transporter protein TnaB which 
helps in internalizing dietary tryptophan which then gets hydrolyzed by tnaA to produce 
indole, pyruvate and ammonia [61,62]. Escherichia coli, one of the bacteria found in 
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mammalian GI tract produces ~600µM indole in suspension culture [58] which has also 
been detected in feces at comparable concentrations [59,60]. Indole had been known as 
bacteria-derived molecule over hundred years [63] however, only recently has it been 
recognized as an intercellular signaling molecule that regulates diverse physiological 
processes in both bacteria and eukaryotic cells. For example, indole has been reported to 
decrease motility and biofilm formation in EHEC [57], increase antibiotic resistance (by 
inducing xenobiotic efflux genes) [64] and decrease virulence in candida albicans [65]. 
Indole also increases intestinal epithelial cell tight junction resistance (likely increased 
protection against invading pathogens) and attenuate pro-inflammatory indicators by 
downregulating NF-κB in human intestinal epithelial cells in vitro [29]. Thus, indole 
appears to be an important intercellular signaling molecule that influences both bacterial 
as well as host cell responses. Several non-indole producing bacteria as well as 
mammalian cells in the GI tract possess enzymatic activity that can modify tryptophan and 
indole to produce other derivatives such as indole-3-propionic acid (identified as a 
powerful anti-oxidant), indoxyl sulphate [66] and 5-hydroxyindole (found in brain) [67]. 
The anti-inflammatory properties of indole as a NF-κB inhibitor and down-
regulator of IL-8 reported by previous work in our laboratory [29] makes it a potential 
therapeutic candidate for inflammatory bowel disease. It is not clearly known yet if indole 
readily diffuses through the membrane of host cells or it requires exporter and importer 
proteins to facilitate its secretion and uptake, respectively [62]. Also, the molecular 
mechanisms involved in indole signaling in host cells are currently not well understood. 
Owing to its structural similarity with other well-known aromatic ligands of the cytosolic 
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ligand-activated aryl hydrocarbon receptor (AHR), such as 2,3,7,8-
tetrachlorodibenzodioxin (TCDD), 6-formylindolo (3,2-b) carbazole (FICZ) [156], indigo 
dye and indirubin [157], we hypothesized in this work that indole might be a potential 
AHR ligand in intestinal epithelial cells that can mediate signaling through the AHR. Jin 
et al. recently demonstrated that indole is an agonist for AHR in Caco-2 intestinal 
epithelial cells based on approximately ten-fold induction in the mRNA levels of the 
canonical AHR-responsive gene cytochrome P450 (CYP1A1) [158]. In the current work 
we investigate a possible signal transduction pathway of indole signaling through 
activation of AHR that regulates host inflammatory signaling.  
The AHR binds to a large number of exogenous aromatic hydrocarbons such as 
dioxins, polycyclic aromatic hydrocarbons (PAH), and polyphenolics and is known to 
regulate xenobiotic mediating enzymes such as cytochrome P450. AHR is sequestered in 
the cytoplasm as an inactive complex with a 90 kDa heat shock protein (HSP90), XAP2 
and p23 in absence of a ligand [101]. Upon ligand binding the activated complex 
translocates into the nucleus and binds to aryl hydrocarbon receptor translocator protein 
(ARNT). AHR-ARNT complex formations induces dissociation of the chaperon proteins 
and AHR-ARNT complex binds to the dioxin response element (DRE) in the promoter 
region of responsive genes such as CYP1A1 (Figure 18). 
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Figure 18. Schematic representation of indole signaling through activation of aryl 
hydrocarbon receptor (AHR). 
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The different chaperon proteins and ARNT tightly control AHR signaling. HSP90 
helps mask the constitutive DNA binding affinity of AHR and maintains the receptor in a 
conformation that promotes high ligand binding affinity. XAP2 prevents ubiquitination of 
AHR prior to ligand binding and p23 prevents nuclear translocation of AHR complex and 
non-specific binding to ARNT in absence of bound ligand. Ligand binding causes 
conformational change in AHR complex (comprising AHR, three chaperon proteins and 
a ligand) that facilitates binding of importin β to the corresponding nuclear localization 
signal (NLS) which in turn promotes nuclear translocation of the complex.  
AHR has been reported to be involved in regulatory T cell (Treg) differentiation 
and down regulation of pro-inflammatory responses and use of natural AHR ligands (for 
example, plant flavonoids) have been reported as potential therapeutics for inflammatory 
disorder [102]. Although AHR activation has been shown to attenuate pro-inflammatory 
responses in hosts [159], specific molecular mechanisms by which it modulates 
inflammation is not fully understood. Tian et al. reported that ligand activated AHR can 
physically bind to activated pro-inflammatory nuclear factor –κ B (NF-κB) to form an 
inactive complex that is unable to translocate into the nucleus which results in mutual 
repression [160]. Based on this observation we extended our mathematical model of 
integrated pro- and anti-inflammatory immune responses centering around NF-κB 
activation (described in Chapter IV) to incorporate indole signaling through AHR and 
study its effect on regulating inflammation through AHR-NFκB interaction. 
NF-κB is a prominent pro-inflammatory transcription factor found in most host 
cell types and is activated by pro-inflammatory stimuli such as LPS (bacterial component) 
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and TNF-α (mammalian cytokine). Upon activation, NF-κB can trigger synthesis of pro-
inflammatory chemokine IL-8. In unstimulated cells, NF-κB is sequestered as an inactive 
complex by inhibitor –κ B α (IκBα). Upon stimulation, the complex is phosphorylated and 
dissociated into free NF-κB and free IκBα in the cytoplasm. Free NF-κB translocates into 
the nucleus and binds to its response elements in the promoter region of the responsive 
genes whereas IκBα is ubiquinated and eventually degraded (Figure 19). 
We developed a mathematical model to describe the signal transduction pathways 
activated by simultaneous indole treatment and pro- inflammatory TNF-α stimulation thus 
leading to AHR and NF-κB activations respectively. Experimental data were used to train 
the model and validate model predictions. 
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Figure 19. Schematic representation of TNF-α-induced signal transduction resulting in 
NF-κB activation and de novo IL-8 synthesis. 
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5.3 MATERIALS AND METHODS 
5.3.1 Model formulation 
In the current work we developed a dynamic computational model comprising 
non-linear ordinary differential equations (ODEs) to investigate molecular mechanisms 
involved in indole-induced attenuation of pro-inflammatory immune responses in 
intestinal epithelial cells based on its ability to down regulate NF-κB activation and 
subsequently inhibit IL-8 synthesis, observed by previous experimental work in our 
laboratory [29]. Until now most of the deterministic computational models relating to host 
immune responses have been focused towards predicting the effect of bacteria-derived 
pro-inflammatory signal such as lipopolysaccharide [161] by triggering pro-inflammatory 
responses in host. The current model is a step towards investigating a potential molecular 
mechanism that might be involved in eliciting host immune responses to indigenous 
bacterial metabolite (indole) with potential anti-inflammatory properties. It is an extension 
of our previously developed model representing cross-talk between pro- and anti-
inflammatory immune responses in host macrophage cells (de novo synthesis of TNF-α 
and IL-10) through NF-κB activation under chronic inflammatory signal (LPS) as 
discussed in Chapter IV. In this chapter we describe the development of an integrated 
model that combines the effects of host-derived pro-inflammatory signal (TNF-α) on 
human intestinal epithelial cells (intra-kingdom) and cross-talk between human intestinal 
epithelial cells and microbiota-derived metabolite indole that influences host immune 
responses (inter-kingdom). Most of the computational models studying host-microbiota 
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interactions focus at metabolic pathways and contributions of microbiota to digestion of 
food in host which in turn help them survive. This is due to the availability of huge sets of 
metagenomic data and genome-scale metabolic models for some bacteria [118]. The 
current work focuses at studying signal transduction and investigation of a possible 
molecular mechanism involved in host immunomodulation by indigenous bacterial 
metabolite, indole. 
The computational model comprises non-linear ordinary differential equations 
(ODE) that describe rate of change of the concentration of a particular component 
(protein/mRNA) involved in the signal transduction network. It is composed of 35 
equations and 43 parameters. The model comprises important biochemical reactions in the 
signal transduction pathways induced by TNF-α (NF-κB activation) and indole (AHR 
activation) stimulation. The starting point of this model is the integrated model developed 
based on pro- and anti-inflammatory immune responses in murine macrophages (Chapter 
IV). The initial values of the parameters and initial protein concentrations are adapted 
from this model. Signal transduction pathway induced by TNF-α that leads to NF-κB 
activation is similar to the base model. No mathematical model has yet been developed 
for indole-induced AHR activation and AHR-NFκB interactions. Hence some of the 
model parameters involved in AHR activation and AHR-NF-κB interaction are initially 
assumed and later estimated using experimental data. 
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The ODE model can be structurally divided into two modules, namely, host-
induced signal transduction under TNF-α stimulation and bacteria-induced signal 
transduction under indole stimulation.  
Host-induced signal transduction through TNF-α stimulation: 
1. In unstimulated cells, NF-κB is sequestered as an inactive complex bound to IκBα. 
2. TNF-α binds to its cell surface receptor. 
3. TNFα+receptor complex activates IKK. 
4. IKK binds to inactive IκBα-NFκB, phosphorylates (activates) and dissociates the 
complex into free IκBα and NFκB. 
5. Free phosphorylated NF-κB translocates into the nucleus of the cell whereas 
phosphorylated IκBα is ubiquinated and degraded in the cytoplasm. 
6. Nuclear phosphorylated NF-κB binds to its response element in the promoter 
regions of IL-8, IκBα and A20 genes and initiates transcription. 
7. IL-8, IκBα and A20 mRNA undergo translation in the cytoplasm. 
8. de novo IL-8 is secreted out of the cell. 
9. de novo cytoplasmic IκBα binds to free cytoplasmic NF-κB as well as translocates 
into the nucleus and sequesters free nuclear NF-κB. Nuclear IκBα- NF-κB 
complex translocates into the cytoplasm. 
10. de novo A20 inactivates IKK. 
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Bacteria-induced signal transduction through indole stimulation: 
1. In unstimulated cells, AHR is sequestered as an inactive complex bound to three 
chaperons, HSP90, XAP2 and p23. 
2. Extracellular indole enters the cell and binds to AHR complex and activates it. 
3. Indole bound AHR complex translocates into the nucleus. 
4. Indole-AHR complex binds to ARNT. 
5. Indole-AHR-ARNT complex binds to dioxin response elements. 
6. No physical binding of AHR or NF-κB complexes takes place in absence of the 
respective ligands for AHR and NF-κB as shown in Figure 20 (A). 
7. ‘n’ fraction of total activated AHR binds to ‘m’ fraction of activated NF-κB. The 
rest (‘1-n’ of activated AHR and ‘1-m’ of activated NF-κB) is free to translocate 
into the nucleus and bind to their respective response elements as shown in Figure 
20 (B). 
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 (A) 
 
 (B) 
 
Figure 20. Simultaneous activation of NF-κB and AHR under TNF-α and indole-
induced signal transduction pathways respectively. (A) In absence of stimulus (B) In 
presence of both TNF-α and indole stimuli. 
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 A third transcription factor has been incorporated into the ODE model and its 
activation is described to be regulated by indole bound AHR. This transcription factor is 
modeled as a black box and is described to induce de novo synthesis of IL-10. Since 
connection between AHR and IL-10 in not clearly understood but IL-10 is known to be 
an important anti-inflammatory cytokine to maintain homeostasis in the GI tract, indole- 
induced AHR activation could be a signal for de novo synthesis of IL-10. We tried to 
investigate this mechanism through our experiments and model predictions.  
 ODEs describing host-induced signal transduction through TNF-α stimulation are 
multiplied with a variable TR where TR is 0 for 4 hours of indole pre-treatment and equal 
to 1 for TNF-α stimulation starting at time t0 post-pretreatment. ODEs corresponding to 
indole-induced signal transduction do not have the term TR. ODEs used for formulating 
the current model and initial values of state variables (different components of the signal 
transduction pathways) are listed in Table 4 and Table 5 respectively. 
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Table 4. Differential equations representing biochemical reactions as used in the ODE model 
describing intra- and inter-kingdom signaling induced by bacterial metabolite indole.  
 
1. 
d[TNF−α]
dt
= TR(−𝑘𝑓1 × [TNF − αsup ][TNF − αR] + 𝑘𝑟1 × [TNFα − TNFαR]) 
2. 
d[TNF−αR]
dt
= TR(−𝑘𝑓1 × [TNF − αsup ][TNF − αR] + 𝑘𝑟1 × [TNFα − TNFαR]) 
3. 
d[TNFα−TNFαR]
dt
= TR(𝑘𝑓1 × [TNF − αsup ][TNF − αR] − 𝑘𝑟1 × [TNFα − TNFαR]) 
4. 
d[IKKn]
dt
= TR(−𝑘𝑓𝑖 × 𝑘𝑖𝑛 × [TNFα − TNFαR] × [IKKn] + 𝑡𝑖 × [IKKa − I𝜅BαNF𝜅Bcyto]) 
where, kin = max [(1 −
[AIC_R ]
[AIC_Rmax]
),0] denoting inhibitory effect of anti-inflammatory cytokine (AIC) 
5. 
d[IKKa]
dt
= TR(𝑘𝑓𝑖 × 𝑘𝑖𝑛 × [TNFα − TNFαR] × [IKKn] − 𝑘𝑘 × 𝑘𝑖𝑛 × [IKKa] × [I𝜅Bα −
NF𝜅Bcyto] − 𝑘𝑎20 × [IKKa] × [A20cyto]) 
6. 
d[IKKi]
dt
= TR(𝑘𝑎20 × [IKKa] × [A20cyto]) 
7. 
d[I𝜅Bα−NF𝜅Bcyto]
dt
= TR(𝑘𝑓2 × [NF𝜅Bcyto][I𝜅Bαcyto] + 𝑒_𝑛𝑓𝑘𝑏_𝑖𝑘𝑏𝑎 × [I𝜅Bα − NF𝜅Bnuclear] × 𝑘𝑣 −
𝑘𝑘 × 𝑘𝑖𝑛 × [IKKa] × [I𝜅Bα − NF𝜅Bcyto]) 
Where kv=nuclear volume/cytoplasmic volume 
8. 
d[IKKa−I𝜅BαNF𝜅Bcyto]
dt
= TR(𝑘𝑘 × 𝑘𝑖𝑛 × [IKKa] × [I𝜅Bα − NF𝜅Bcyto] − 𝑡𝑖 × [IKKa − I𝜅BαNF𝜅Bcyto]) 
9. 
d[NF𝜅Bcyto]
dt
= TR(−𝑘𝑓2 × [NF𝜅Bcyto][I𝜅Bαcyto] + 𝑡𝑖 × [IKKa − I𝜅BαNF𝜅Bcyto] − 𝑖𝑙𝑛 × 𝑘𝑖𝑛 ×
[NF𝜅Bcyto]) 
10. 
d[NF𝜅Bnuclear]
dt
= TR((1 − m) × 𝑖_𝑛𝑓𝑘𝑏 × 𝑘𝑖𝑛 ×
[NF𝜅Bcyto]
kv
− 𝑘𝑓2 × [NF𝜅Bnuclear][I𝜅Bαnuclear]) 
11. 
d[I𝜅Bαphopsho
dt
= TR(𝑡𝑖 × [IKKa − I𝜅BαNF𝜅Bcyto] − 𝑘𝑑𝑒𝑔𝐼𝜅𝐵𝛼 × [I𝜅Bαcyto]) 
12. 
d[A20mRNA]
dt
= TR(𝑆𝑚 × 𝑝 ×
[NF𝜅Bnuclear]
C+[NF𝜅Bnuclear]
− 𝐷𝑚 × [A20mRNA]) 
13. 
d[A20cyto]
dt
= TR(𝑎20𝑡𝑟𝑎𝑛𝑠 × [A20mRNA] − 𝑘𝑑𝑒𝑔𝐴20 × [A20cyto]) 
14. 
d[I𝜅BαmRNA]
dt
= TR(𝑆𝑚 × 𝑝 ×
[NF𝜅Bnuclear]
C+[NF𝜅Bnuclear]
− 𝐷𝑚 × [I𝜅BαmRNA]) 
15. 
d[I𝜅Bαcyto]
dt
= TR(−𝑘𝑓2 × [NF𝜅Bcyto][I𝜅Bαcyto] + 𝑖𝜅𝑏𝛼𝑡𝑟𝑎𝑛𝑠 × [I𝜅BαmRNA] − 𝑖_𝑖𝑘𝑏𝑎 × [I𝜅Bαcyto] + 𝑒_𝑖𝑘𝑏𝑎 ×
[I𝜅Bαnuclear] × 𝑘𝑣) 
16. 
d[IL−8mRNA]
dt
= TR(𝑆𝑚 × 𝑝 ×
[NF𝜅Bnuclear]
C+[NF𝜅Bnuclear]
− 𝐷𝑚 × [IL − 8mRNA]) 
17. 
d[IL−8cyto]
dt
= TR(𝑖𝑙8𝑡𝑟𝑎𝑛𝑠 × [IL − 8mRNA] − 𝑘𝑑𝑒𝑔𝐼𝐿8 × [IL − 8cyto]) 
18. 
d[IL−8sup]
dt
= 𝑘𝑠𝑒𝑐𝐼𝐿8 × [IL − 8cyto] ×
0.36
200
− 𝑘𝑑𝑒𝑔𝐼𝐿−8𝑠𝑢𝑝 × [IL − 8sup] 
19. 
d[I𝜅Bαnuclear]
dt
= TR(−𝑘𝑓2 × [NF𝜅Bnuclear][I𝜅Bαnuclear] + 𝑖_𝑖𝑘𝑏𝑎 ×
[I𝜅Bαcyto]
kv
− 𝑒𝑘𝑖 × [IkBαnuclear]) 
20. 
d[I𝜅Bα−NF𝜅Bnuclear]
dt
= TR(𝑘𝑓2 × [NF𝜅Bnuclear][I𝜅Bαnuclear] − 𝑒_𝑛𝑓𝑘𝑏_𝑖𝑘𝑏𝑎 × [I𝜅Bα −
NF𝜅Bnuclear]) 
21. 
d[Indole]
dt
− 𝑘𝑓3 × indtransport × [indole][AHRcomplex] + 𝑘𝑟3 × [indole − AHRcyto] 
22. 
d[AHR complex]
dt
= −𝑘𝑓3 × indtransport ×  [indole][AHRcomplex] + 𝑘𝑟3 × [indole − AHRcyto] 
23. 
d[indole−AHR cyto 
]
dt
= 𝑘𝑓3 × indtransport ×  [indole][AHRcomplex] − 𝑘𝑟3 × [indole − AHRcyto] 
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Table 4. Continued. 
 
24. 
d[indole−AHR complexnuclear ]
dt
= (1 − 𝑛) × 𝑖_𝑖𝑖𝑛𝑑𝑜𝑙𝑒𝑎ℎ𝑟 ×
[indole−AHRcomplexcyto]
kv
− 𝑘𝑎ℎ𝑟𝑎𝑟𝑛𝑡 × [indole −
AHR complexnuclear ] × [ARNT] 
25. 
d[ARNT
 
]
dt
= 𝑘𝑎ℎ𝑟𝑎𝑟𝑛𝑡 ×  [indole − AHR complexnuclear ] × [ARNT] 
26. 
d[indole−AHR−ARNT nuclear ]
dt
= 𝑘𝑎ℎ𝑟𝑎𝑟𝑛𝑡 × [indole − AHR complexnuclear ] × [ARNT] 
27. 
d[indole−AHR−NFκB complex cyto 
]
dt
= TR(𝑘𝑎ℎ𝑟𝑛𝑓𝑘𝑏 × n × [indole − AHRcyto]× m ×  [NF𝜅Bcyto] 
28. 
d[TF_AIcyto 
]
dt
= −𝑘𝑓4 ×  [TF_IL10cyto 
] × (1 − n) × [indole − AHR complexnuclear ]  
29. 
d[TF_AI_phosphocyto 
]
dt
= 𝑘𝑓4 ×  [TF_IL10cyto 
] × (1 − n) × [indole − AHR complexnuclear ]  − 
𝑖_𝑡𝑓_𝑎𝑖 × [TF_AInuclear] 
30. 
d[TF_AI_phosphonuclear 
]
dt
=  𝑖_𝑡𝑓_𝑎𝑖 × [TF_AInuclear] 
31. 
d[IL−10mRNA]
dt
= TR × [a × 𝑆𝑚 × 𝑝 ×
[NF𝜅Bnuclear]
C+[NF𝜅Bnuclear]
]  + b × 𝑆𝑚_𝑖𝑙10 × 𝑝 ×
[TF_AInuclear]
C_TF_AI+[TF_AInuclear]
−
𝐷𝑚 × [IL − 10mRNA] 
32. 
d[IL−10cyto]
dt
= 𝑖𝑙10𝑡𝑟𝑎𝑛𝑠 × [IL − 10mRNA] − 𝑘𝑠𝑒𝑐𝐼𝐿10 × [IL − 10cyto] − 𝐷𝑛 × [IL − 10cyto] 
33. 
d[IL−10sup]
dt
= −𝑘𝑓4 × [IL − 10sup][IL − 10R] + 𝑘𝑟4 × [IL10 − IL10R] + 𝑘𝑠𝑒𝑐𝐼𝐿10 × [IL −
10cyto] ×
0.36
200
− 𝑘𝑑𝑒𝑔𝐼𝐿−10𝑠𝑢𝑝 × [IL − 10sup] 
34. 
d[IL−10R]
dt
= −𝑘𝑓4 × [IL − 10][IL − 10R] + 𝑘𝑟4 × [IL10 − IL10R] 
35. 
d[IL10−IL10R]
dt
= 𝑘𝑓4 × [IL − 10sup][IL − 10R] − 𝑘𝑟4 × [IL10 − IL10R] 
 
 
 
 
Table 5. State variables and their initial values as used in intra- and inter-kingdom 
signaling ODE model. 
 
 
Sr. No. 
 
 
State variables 
 
Initial values, µM 
1.  TNF-α Input concentrations 
2.  TNF-αR 1.0 × 10−1 
3.  TNFα-TNFαR 0 
4.  IKKneutral 2.0 × 10−1 
5.  IKKactive 0 
6.  IKKinactive 0 
7.  IκBα-NFκBcyto 2.5 × 10−1 
8.  IKK- IκBαNFκB 0 
9.  NFκBcyto 9.0 × 10−4 
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Table 5 Continued. 
 
 
Sr. No. 
 
 
State variables 
 
Initial values, µM 
10.  NFκBnuclear 0 
11.  IκBαphopsho 0 
12.  A20mRNA 0 
13.  A20cyto 4.8 × 10−3 
14.  IκBαmRNA 0 
15.  IκBαcyto 2.5 × 10−3 
16.  IL-8-αmRNA 0 
17.  IL-8-αcyto 0 
18.  IL-8-αsup 0 
19.  IκBαnuclear 0 
20.  IκBα-NFκBnuclear 0 
21.  Indole Input concentrations 
22.  AHR complexcyto 2.5 × 10−2 
23.  Indole-AHR complexcyto 0 
24.  Indole-AHR complexnuclear 0 
25.  ARNT 0 
26.  Indole-AHR-ARNTnuclear 0 
27.  Indole-AHR-NFκBcyto 0 
28.  TF_AIcyto 2.5 × 10−1 
29.  TF_AI_phospho cyto  3 × 10−4 
30.  TF_AI_phosphonuclear 0 
31.  IL-10mRNA 0 
32.  IL-10cyto 0 
33.  IL-10supernatant 4.6 × 10−6 
34.  IL-10R 1.0 × 10−1 
35.  IL10-IL10R 0 
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5.3.2 Parameter selection and estimation 
 The parameter estimation problem for a dynamic system described by ordinary 
differential equations (ODEs) can be mathematically formulated as follows: 
 
 
2
ˆmin  ik ik ik
p
i k
w y y  (5.1) 
s.t.    , ,x t f x u p ,   00 x x  (5.2) 
  y g x  (5.3) 
  lb ubx x x  (5.4) 
  lb ubp p p  (5.5) 
 
where yik and ŷik are the simulated and experimental data of the i-th component at sampling 
time tk, respectively as shown in equation (5.1). In equation (5.2), x are the state variables 
of the dynamic system (as listed in Table 5), i.e., concentrations of individual components, 
with initial values x0, u are the inputs to the system and p are the parameters to be 
estimated. The simulated output vector y in equation (5.3) is validated by experimental 
data of concentrations of intracellular phosphorylated NF-κB (relative to the unstimulated 
control) and extracellular IL-8 in cell culture supernatant. In addition, the state variables 
x and parameters p are restricted within certain ranges as shown in equations (5.4) and 
(5.5), determined by the underlying biology and prior knowledge based on mathematical 
models [31,32,112]. 
 94 
 
The experiments are conducted with different levels of inputs u (i.e., three different 
concentrations of TNF-α; 0.1, 1, and 10 ng/ml, and four different concentrations of indole; 
0, 0.25, 0.5, and 1 mM). A total of 12 sets of measured outputs ŷik corresponding to 
different experimental conditions are obtained. These 12 measurements are randomly 
partitioned into training sets (to estimate model parameters) and validation sets (to validate 
model predictions).  
Before performing parameter estimation, a local sensitivity analysis [162,163] is 
performed to identify the parameters that need to be estimated to fit the experimental data. 
In this method, sensitivity vectors for each parameter are calculated and clustered into a 
dendrogram. A cut off value for the clustering algorithm is chosen, in this case 0.05 
resulting in the selection of eight parameters. The normalized sensitivity magnitudes of 
the parameters are reflected in the histograms in Figure 21. The y-axis represents 
correlation among parameters ranging from 0 to 1. The red line represents the cut-off value 
which results in clustering the entire set of parameters into eight pairwise indistinguishable 
groups (illustrated in different colors). The parameters with the largest sensitivity 
magnitude within each group are selected for estimation (highlighted in red). 
 Three other parameters (i.e., n, a, and b) were determined to be of significance a 
priori to investigate crosstalk between the AHR and NF-κB interactions. Therefore, a total 
of eleven parameters have been estimated using the experimental data. 
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Figure 21. Representation of local sensitivity analysis results used for selecting 
parameters of intra- and inter-kingdom signaling ODE model that are to be estimated. The 
normalized sensitivity magnitudes of the parameters are reflected in the histograms. The 
y-axis represents correlation among parameters ranging from 0 to 1. The red line 
represents the cut-off value which results in clustering the entire set of parameters into 
eight pairwise indistinguishable groups (illustrated in different colors). The parameters 
with the largest sensitivity magnitude within each group are selected for estimation 
(highlighted in red). 
 
 
 
 
A Trust-Region optimization technique is used to estimate the selected parameters. 
In this technique, an optimization algorithm is applied which requires repeated evaluation 
of the objective function and its gradients by numerical integration of the ODEs [145,164]. 
The eleven parameters selected in the previous step are estimated using the randomly 
selected training data sets. List of all parameters used in the intra- and inter-kingdom 
signaling ODE model are described in Table 6. 
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Table 6. List of parameters used in the intra- and inter-kingdom signaling ODE model. 
Estimated parameters after model optimization with experimental data are indicated in 
boldface. 
 
 
Sr. No. 
 
Parameter Description Value Units Comment 
1. 1
. kv Nuclear: Cytoplasmic (Volume) 4.094 NA Estimated 
2. 2
. kf1 TNF-α binding to receptor 1.583  (µM−s)−1 Estimated 
3. 3
. kr1 
Dissociation of TNF-α + receptor 
complex 
1.25 × 
10−3  
(µM−s)−1 
Rangamani et al. (2007) 
[112] 
4. 4
. kfi IKK activation 0.85  s−1 Estimated 
5.  
kk Association of IKK with IκBα-NFκB 1.0 (µM−s)−1 
Lipniacki et al. (2004) 
[31] 
6. 5
. ti 
Catalytic breakdown of IKK-IκBα-
NFκB 
6.7 × 10−5  s−1 Estimated 
7. 3
. k_a Inactivation of IKK by A20 2.5 × 10−4  (µM-s)−1 Assumed 
8.  
kf2 IκBa and NF-κB association 2.5 × 10−3 (µM−s)−1 Assumed 
9.  
i_ikba IκBα nuclear import 
5.44 × 
10−3 
s−1 Estimated 
10.  
e_ikba IκBα nuclear export 4.094 s−1 Estimated 
11.  
e_nfkb_ikba IκBα-NFκB nuclear export 
1.00 × 
10−2 
s−1 
Lipniacki et al. (2004) 
[31] 
12. 4
. kf4 IL-10 binding to receptor 
2.50 × 
10−4 
(µM−s)−1 Assumed 
13. 5
. kr4 
Dissociation of IL-10 + receptor 
complex 
6.11 × 
10−4  
(µM−s)−1 Assumed 
14. 6
. i_nfkb NF-κB nuclear import 
1.52 × 
10−3 
s−1 Estimated 
15. 7
. e_nfkb_ikba NF-κB nuclear export 0.01 s−1 
Lipniacki et al. (2004) 
[31] 
16. 8
. ind_transport Indole transport into cell cytoplasm 1.0 × 10−3 s−1 Assumed 
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Table 6. Continued. 
 
 
Sr. No. 
 
Parameter Description Value Units Comment 
17. 9
. i_ind_ahr Indole-AHR nuclear transport 
1.52 × 
10−4 
s−1 Assumed 
18. 1
0
. 
i_TF_AI 
Phosphorylated TF_ anti-
inflammatory nuclear import 
1.52 × 
10−3 
s−1 Assumed 
19.  
k_ahr_arnt Indole bound AHR-ARNT binding 2.5 × 10−3 (µM−s)−1 Assumed 
20.  
k_ahr_nfkb 
Indole bound AHR-activated NF-κB 
binding 
2.5 × 10−3 (µM−s)−1 Assumed 
21. 1
1
. 
a20trans A20 translation 
5.00 × 
10−1 
s−1 
Lipniacki et al. (2004) 
[31] 
22. 1
2
. 
kdegA20 Degradation of A20 protein 
3.00 × 
10−4 
s−1 
Lipniacki et al. (2004) 
[31] 
23. 1
3
. 
iκbαtrans IκBα translation 6.6 × 10−1 s−1 Estimated 
24. 1
4
. 
kdegIκBα Degradation of phosphorylated IκBα 
1.28 × 
10−4 
s−1 
Assumed half-life of 90 
min 
25.  
il8trans IL-10 translation 
5.00 × 
10−1 
s−1 
Lipniacki et al. (2004) 
[31] 
26.  
ksecIL8 
Secretion of IL-8 from cytoplasm to 
supernatant 
5.16 × 
10−6 
s−1 Assumed 
27.  
kdegIL8sup Degradation of IL-8 in supernatant 
7.46 × 
10−7 
s−1 Assumed 
28. 1
5
. 
il10trans IL-10 translation 
5.00 × 
10−1 
s−1 
Lipniacki et al. (2004) 
[31] 
29. 6
. ksecIL10 
Secretion of IL-10 from cytoplasm to 
supernatant 
2.03 × 
10−5 
s−1 Assumed 
30. 1
7
. 
kdegIL10sup Degradation of IL-10 in supernatant 
7.40 × 
10−5 
s−1 
Half-life of 2.6 h in 
supernatant. Fedorak et al. 
[148] 
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Table 6. Continued. 
 
 
Sr. No. 
 
Parameter Description Value Units Comment 
31. 1
8
. 
Dn Degradation of intracellular cytokine 
1.04 × 
10−2 
s−1 Huang et al. (2008) [32] 
32. 1
9
. 
kf4 
Indole-AHR complex induced 
activation TF_anti-inflammatory  
2.5 × 10−4  (µM−s)−1 Assumed 
33. 2
0
. 
Sm Transcription due to NF-κB 
1.00 × 
10−1 
s−1 Huang et al. (2008) [32] 
34. 2
1
. 
Sm_il10 
IL-10 translation due to TF_anti-
inflammatory 
1.5 s−1 Maiti et al. [8] 
35. 2
2
. 
p Transcription parameter 
5.00 × 
10−3 
µM Huang et al. (2008) [32] 
36. 2
3
. 
Dm Degradation of mRNA 
1.04 × 
10−2 
s−1 Huang et al. (2008) [32] 
37. 2
4
. 
C 
Maximum NF-κB concentration in 
nucleus 
1.08 × 
10−1 
µM Huang et al. (2008) [32] 
38. 2
5
. 
CTF_AI 
Maximum TF_anti-inflammatory 
concentration in nucleus 
5.00 × 
10−2 
µM Assumed 
39. 2
6
. 
IL10-IL10Rmax IL10-IL10R maximum concentration 
2.56 × 
10−6 
µM Assumed 
40.  
m 
Fraction of activated NF-κB 
binding to AHR in the cytoplasm 
0.948 NA Estimated 
41.  
n 
Fraction of activated AHR binding 
to NF-κB in the cytoplasm 
0.733 NA Estimated 
42.  
a 
Impact of NF- κB on IL-10 
transcription 
0.879 NA Estimated 
43. b 
b 
Impact of TF_anti-inflammatory 
on IL-10 transcription 
0.314 NA Estimated 
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5.3.3 Cell culture and experimental-set up 
All experiments were performed in human colon-cancer cell line HCT-8 (ATCC, 
Manassas, VA) derived from enterocytes at the junction of large and small bowel. HCT-8 
cells were routinely cultured in Rosewell Park Memorial Institute (RPMI) 1640 medium 
with 10% equine serum, 1mM sodium pyruvate, 10mM HEPES, 100 U/ml penicillin and 
100 µg/ml streptomycin at 37ᵒC and 5% CO2 according to standard ATCC protocols. 
HCT-8 cells were seeded in tissue culture treated well plates and allowed to attach 
overnight before indole treatment and TNF-α stimulation. 
5.3.3.1 Indole treatment of colonic epithelial cells 
HCT-8 cells were pre-treated with indole (Acros Organics, New Jersey, NJ) at titer 
concentrations of 0, 0.25, 0.5 and 1mM (initially dissolved in N,N-dimethylformamide 
and subsequently diluted in growth medium; final DMF concentration < 0.2%) in 
triplicates for 4 hours prior to TNF-α stimulation. Cells were continued to be exposed to 
corresponding concentrations of indole in presence TNF-α. 
5.3.3.2 TNF-α stimulation of colonic epithelial cells 
HCT-8 cells were stimulated with different concentrations (0.1 1 and  
10 ng/mL) of recombinant human TNF-α (R&D Systems, Minneapolis, MN, USA) diluted 
in growth medium. 
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5.3.3.3 Transcription factor NF-κB quantification by ELISA 
Indole treated and TNF-α stimulated (under conditions mentioned above) whole 
cells were used to measure phosphorylated NF-κB 5, 15, 30, 45, 60, 120 and 240 minutes 
post-TNF-α stimulation. Concentrations of phosphorylated NF-κB in HCT-8 epithelial 
cells were determined using a commercially-available enzyme-linked-immunosorbent 
assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer’s suggested protocol.  
5.3.3.4 IL-8 quantification by ELISA 
Culture supernatants were collected 4, 8 and 12 hours post-TNF-α stimulation to 
measure de novo synthesized IL-8 concentrations by commercially available enzyme-
linked immunosorbent assay (ELISA) kits (Thermo Scientific, Rockford, IL, USA), using 
the manufacturer’s suggested protocol.  
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5.4 RESULTS AND DISCUSSION 
The mathematical model presented in this section is based on observations of 
previous research work from our laboratory that showed indole-induced down-regulation 
NF-κB activation and de novo IL-8 synthesis in HCT-8 cells [29]. However, the molecular 
mechanisms underlying indole’s effects are not well understood. We investigated a 
possible mechanism of indole signaling through AHR activation and subsequent 
interaction with activated NF-κB, as suggested by Tian et al. [160]. We monitored NF-κB 
(p65) phosphorylation (activation) at different time points (5, 15, 30, 45, 60, 120 and 240 
minutes post-TNF-α stimulation) and measured de novo IL-8 concentrations (2, 4, 8, 12 
hours post-TNF-α stimulation) under different concentrations of TNF-α stimulations (0.1, 
1, 10 ng/mL) and indole treatment (0, 0.25, 0.5 and 1mM) to establish dynamics of TNF-
α and indole-induced intra- and inter-kingdom signaling. 
The experimental data obtained for phosphorylated NF-κB (Rel A-p65) in TNF-α 
stimulated HCT-8 cells was normalized to unstimulated control at time t0 to get a relative 
value. The unstimulated control has a value of 1 for phosphorylated NF-κB at time t when 
normalized to the phosphorylated NF-κB at time t0 (TNF-α stimulation starts at time t0). 
Thus, the data for normalized phosphorylated NF-κB for all the conditions have values 
higher than 1. 
  
 102 
 
 Figure 22 (A) shows levels of normalized phosphorylated NF-κB in HCT-8 cells 
after 4 hour pre-treatment with 0, 0.25, 0.5 and 1mM indole and 0.1 ng/mL TNF-α 
stimulation (in presence of indole). Phosphorylated NF-κB exhibits dose and time-
dependent responses to indole concentrations. The phosphorylated levels of NF-κB are 
significantly reduced by 1mM indole treatment and the effect is observed from 5 minutes 
to 120 minutes post-TNF-α stimulation. In 0.5mM indole treated cells, significant 
reduction in phosphorylated NF-κB is observed after 30 minutes of TNF-α stimulation 
whereas 0.25mM indole treatment is able to reduce phosphorylated NF-κB levels only at 
45 and 120 minutes post-TNF-α stimulation. Figure 22 (B) represents normalized 
phosphorylated NF-κB levels under indole treatment and 1 ng/mL TNF-α stimulation. 
Statistically significant reduction in phosphorylated NF-κB is observed for 0.5 and 1mM 
indole treatment at 120 minutes post-TNF-α stimulation only. As shown in Figure 22 (C), 
no concentration of indole treatment is able to significantly reduce activation of NF-κB 
under 10ng/mL TNF-α stimulation.  
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Figure 22. Experimental data of phosphorylated NF-κB (relative to unstimulated control 
at time t0) in HCT-8 cells under different concentrations of indole treatment and TNF-α 
stimulation. (A) 0.1 ng/mL TNF-α stimulation; (B) 1 ng/mL TNF-α stimulation; (C) 10 
ng/mL TNF- α stimulation. Statistical significance of phosphorylated NF-κB inhibition 
for P < 0.05 (*) and P < 0.01 (**) are indicated in the plots. 
  
(A) 
 
 
(B) 
 
 
(C) 
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Figure 23 shows the concentrations of de novo synthesized IL-8 in HCT-8 cells in 
response to TNF-α stimulation and indole treatment. All concentrations of indole 
treatment used (0.25, 0.5 and 1 mM) were able to significantly down regulate IL-8 
production in HCT-8 cells when stimulated with 0.1 ng/mL TNF-α for 2, 4, 8 and 12 hours 
as shown in Figure 23 (A). However, at a TNF-α concentration of 1 ng/mL, only 1 mM 
indole treatment was able to significantly reduce IL-8 production at all four time points 
(2, 4, 8, 12 hours post-TNF-α stimulation). Whereas, 0.5 mM indole treatment 
significantly down regulated IL-8 production for 4 hours and 0.25mM significantly 
reduced IL-8 synthesis only till 2 hours post-TNF-α stimulation at 1 ng/mL as shown in 
Figure 23 (B). In Figure 23 (C), under 10 ng/mL TNF-α stimulation all three 
concentrations of indole treatment significantly reduced IL-8 production until 2 hours 
post-stimulation. Beyond that, only 0.5 and 1mM indole concentrations were effective at 
downregulating IL-8 synthesis 4 hours post-TNF-α stimulation with no significant 
reduction observed after 4 hours. 
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Figure 23. Experimental data of de novo synthesized IL-8 in HCT-8 cells under different 
concentrations of indole treatment and TNF-α stimulation. (A) 0.1 ng/mL TNF-α 
stimulation; (B) 1 ng/mL TNF-α stimulation; (C) 10 ng/mL TNF- α stimulation. Statistical 
significance of IL-8 inhibition for P < 0.05 (*) and P < 0.01 (**) are indicated in the plots.  
(A) 
 
 
(B) 
 
 
(C) 
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 A portion of the experimental data (randomly selected) was used to train the 
computational model and optimize model parameters under different exposure conditions. 
Model predictions for phosphorylated NF-κB and extracellular IL-8 were validated using 
the remaining data set. Figure 24 shows the comparison between model simulations and 
experimental data for intracellular phosphorylated NF-κB (normalized to unstimulated 
control at t0). It can be seen that the simulation of both randomly selected training sets and 
validation sets agree with the experimental data with reasonable accuracy indicating that 
the parameter estimation is numerically robust. 
 
 
 
 
(A) 
 
 
 
Figure 24. Comparison of model simulation with experimental data for phosphorylated 
NF-κB normalized to unstimulated control in HCT-8 cells under indole treatment and 
TNF-α stimulation. (A) 0.1 ng/mL TNF-α stimulation; (B) 1 ng/mL TNF-α stimulation; 
(C) 10 ng/mL TNF-α stimulation. 
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(B) 
 
 
 
(C) 
 
 
Figure 24. Continued. 
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Comparison of model predictions and experimental data for extracellular IL-8 
under different inputs of TNF-α stimulation and indole treatment are shown in Figure 25. 
The model simulation of both training sets and validation sets show reasonably good 
agreement with experimental data. The model predictions for de novo IL-8 synthesis are 
able to capture the overall IL-8 concentration increase with an increasing TNF-α in a dose-
dependent manner with a maximum of ~7000 pg/mL for 0.1ng/mL TNF-α stimulation, 
~15,000 pg/mL for 1 ng/mL TNF-α stimulation and ~25,000 pg/mL for 10 ng/mL TNF-α 
stimulation. 
 
 
 
 
(A) 
 
 
 
Figure 25. Comparison of model simulation with experimental data for de novo IL-8 
synthesis in HCT-8 cells under indole treatment and TNF-α stimulation. (A) 0.1 ng/mL 
TNF-α stimulation; (B) 1 ng/mL TNF-α stimulation; (C) 10 ng/mL TNF-α stimulation. 
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(B) 
 
 
 
(C) 
 
 
 
Figure 25. Continued. 
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In our model we have incorporated two mechanisms for the down-regulation of 
NF-κB through indole-activated AHR. First, the physical binding of activated 
transcription factors NF-κB and AHR observed experimentally by Tian et al. [160] which 
leads to cytoplasmic sequestration of NF-κB. Second, AHR-induced activation has been 
modeled to induce, either directly or indirectly through other transcription factors, the 
expression of an anti-inflammatory cytokine that down regulates NF-κB signaling. Based 
on our work [8] and prior studies [149], we hypothesized that the anti-inflammatory 
cytokine induced by AHR signaling is IL-10, given its ability to inhibit IKK activation as 
well as nuclear translocation of phosphorylated NF-κB [142,143]. 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis 
of IL-10 expression in indole treated Caco-2 (human epithelial adenocarcinoma) cells 
showed a dose dependent increase in IL-10 mRNA in response to indole treatment. 
However, we were unable to detect an increase in IL-10 protein using ELISA or flow 
cytometry presumably due to the low expression of IL-10 by these cells. We speculate that 
the activation of IL-10 is mediated by the transcription factor Sp1 that is known to regulate 
IL-10 production [165] and is known to physically interact with the AHR protein [166]. It 
is also possible that the observed effect is mediated by an anti-inflammatory cytokine other 
than IL-10 such as TGF-β as AHR activation has been reported to induce differentiation 
of naïve T-cells to TGFβ producing regulatory T cells [167].  
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Our experimental data shows that 1mM indole is able to significantly down 
regulate TNF-α induced NF-κB activation from 5 minutes to 120 minutes and subsequent 
synthesis of IL-8 from 2 to 12 hours post-TNF-α stimulation at 0.1 ng/mL. Significant IL-
8 inhibition is observed from 2 to 12 hours under 1 ng/mL TNF-α stimulation and only 
until 4 hours under 10 ng/mL TNF-α stimulation (though NF-κB down regulation is not 
statistically significant at under these two conditions). If the physical association between 
NF-κB and AHR were to be the mechanism through which inflammatory signaling is 
attenuated, our data are in support as more NF-κB would be expected to be activated at 
higher concentrations of TNF-α (i.e., more NF-κB is present than AHR can bind to). This 
is a distinct possibility as the abundance of NF-κB in cell cytoplasm is most likely many 
folds higher than AHR. 
In addition, although 0.25 and 0.5 mM indole treatments do not show significant 
reduction in phosphorylated NF-κB levels, they inhibit IL-8 synthesis to varying degrees 
and time-points post-TNF-α stimulation. This suggests the involvement of a different 
transcription factor that might mediate pro-inflammatory responses and induce IL-8 
production. One possible candidate could be CCAAT enhancer-binding protein β 
(CEBPβ; also known as NF-IL6) as it has been reported to activate transcription of IL-8 
in synergy with NF-κB [89]. AHR has been shown to repress CEBPβ activation in addition 
to other transcription factors involved in acute phase response [168].  
The model discussed in this chapter is a step towards assimilating our knowledge 
about host-microbiota interactions, investigating a potential signaling pathway induced by 
indigenous bacterial metabolite and develop a quantitative understanding of the inter-
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kingdom signaling in mammalian hosts. This model can be further used to study the 
molecular mechanisms involved in immunomodulatory effects of other tryptophan 
derivatives found in the GI tract of hosts, such as tryptamine and 5-hydroxyindole [68]. 
The model developed in this work can be used to incorporate other transcription factors 
such as CEBPβ and Sp1 to represent the molecular mechanism involved in indole-induced 
anti-inflammatory immune responses of host cells and use experimental data to estimate 
the unknown parameters of the model. 
  
 113 
 
CHAPTER VI 
CONCLUSIONS AND FUTURE WORK 
6.1 CONCLUSIONS 
The increasing incidence of inflammatory disorders such as inflammatory bowel 
disease and multiple factors that significantly contribute to the initiation of the disorder 
such as genetics, diet and dysbiosis are not fully understood and hence motivated us in 
investigating the role of anti-inflammatory cytokines and intestinal microbiota that help 
maintain homeostasis. The interaction between intestinal microbiota residing in mammals 
and their immunomodulatory effects is rapidly emerging as an attractive area of research. 
The limiting factor in studying microbiota and metabolites secreted by them is the 
difficulty in culturing indigenous bacteria under laboratory conditions. Coupling 
mathematical modeling and experimental techniques could bridge the gap between the 
known and the unknown by understanding molecular mechanisms of host-microbiota 
interactions from predictions of experimentally validated models. Most of the 
computational models related to host-microbiota interactions are stochastic due to the 
unknown mechanisms involved in inter-kingdom signaling. In this dissertation we 
developed deterministic models based on biochemical reactions involved in intra-cellular 
signaling (as suggested by prior and current experimental data) to investigate possible 
mechanisms for maintaining immune homeostasis in the host.  
In Chapter IV we developed an experimentally validated mathematical model that 
represented pro- and anti-inflammatory immune responses through de novo synthesis of 
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TNF-α (pro-inflammatory) and IL-10 (anti-inflammatory) under continuous LPS 
stimulation (mimicking chronic inflammation). We found that LPS stimulation of 
macrophages induces TNF-α synthesis which is then attenuated by subsequent synthesis 
of IL-10. This is likely one of the mechanisms utilized to regulate inflammation and 
maintain homeostasis in healthy individuals. Most of the inflammatory disorders are 
accompanied with high TNF-α and low IL-10 concentrations in the body. The use of de-
novo synthesized anti-inflammatory cytokines could be a good therapeutic modality for 
alleviating chronic inflammation in patients suffering from auto-inflammatory disorders, 
provided the anti-inflammatory can be selectively induced.  
In Chapter V we studied intra- and inter-kingdom signaling in hosts that arise from 
indigenous bacterial metabolite indole-induced host immune responses exhibited by down 
regulation of transcription factor NF-κB and chemokine IL-8 through signal transduction 
pathway involving activation of AHR host cells. With the extensive data sets generated, 
we could observe a time and dose dependent efficiency of indole as an anti-inflammatory 
molecule. Our data shows that 1mM indole is able to down regulate NF-κB activation and 
IL-8 synthesis for 2, 4, 8 and 12 hours post-TNF-α stimulation at low TNF-α dose such as 
0.1 ng/mL. It can inhibit IL-8 production but not down regulate NF-κB at higher 
concentrations of TNF-α, indicating a possibility of another transcription factor (e.g. 
CEBPβ) that can induce IL-8 and is a possible target for indole bound AHR. 
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The contributions made by this dissertation can be summarized as follows: 
1. The mathematical model was developed for pro- and anti-inflammatory responses 
in murine macrophage cell line. However, this is not restricted to macrophages and 
can be used for other inflammatory cell types as well. The parameters would need 
to be adjusted accordingly depending on the rates of the specific biochemical 
reactions represented in the model. Reaction rates are known to vary from one cell 
type to another. This model will be able to predict if the particular mammalian cell 
will be able to synthesize enough IL-10 upon inflammatory stimulus to counter-
balance TNF-α produced by the cells and hence maintain homeostasis.  
2. A mathematical model was developed for host-microbiota interaction through 
indole signaling in intestinal epithelial cells. This model is not limited to indole 
signaling and can be used to study the effects of any microbiota metabolite (e.g., 
other tryptophan-derived molecules, derivatives of indole or potential AHR 
ligands such as plant flavonoids) to investigate their effects on inflammatory 
signaling in intestinal epithelial cells or any other cell type. It can also be used as 
the basis for incorporating other transcription factors that are known to be activated 
by indole to study its effect on NF-κB activation and IL-8 synthesis. 
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6.2 RECOMMENDATIONS FOR FUTURE WORK 
 The primary focus of this dissertation is to develop deterministic models to study 
integrated pro- and anti-inflammatory immune responses in mammalian host under 
bacterial components LPS (pro-inflammatory signal) and indole (anti-inflammatory 
signal) as part of intra- and inter-kingdom signaling in host.  
Some recommendations for future work are as follows: 
1. Investigation of de novo synthesized anti-inflammatory cytokine in mammalian 
host cells under indole treatment. As indicated in Chapter V of this dissertation, 
the bacterial metabolite indole is able to attenuate pro-inflammatory markers such 
as activation of NF-κB and de novo synthesis of IL-8. Though physical binding of 
indole activated AHR and TNF-α activated NF-κB can explain the decrease in 
available free NF-κB and therefore reduction in IL-8 production, there might a 
second level of regulation that is involved. It could be activation of another 
transcription factor such as Sp1 that is known to regulate IL-10 production. We 
also observed that indole can increase IL-10 mRNA in a dose dependent manner. 
It would be worth investigating if indole upregulates other anti-inflammatory 
cytokines such as TGF-β in intestinal epithelial cells as TGF-β is known to be 
found in GI tract and its involvement in maintaining GI homeostasis is well 
established [169]. 
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2. Indole has been reported to exhibit dual characteristics; at low concentrations 
(~50-100 µM) it is an AHR agonist and acts as an antagonist of TCDD-mediated 
induction of CYP1A1 at higher concentrations (~500 – 1000 µM) [158]. Agonist 
and antagonist behavior of several ligands have been attributed to their preference 
for specific binding sites under different conditions, thereby leading to distinct 
conformational changes in the receptor that results in the induction of different 
signals. The specific criteria for indole’s dual characteristic is not well understood. 
It would be interesting to investigate what leads to the duality in indole’s function 
as a potential AHR ligand. In the GI tract indole is present in conjunction with 
other potential endogenous ligands for AHR. Hence, studying indole’s preference 
for specific binding sites on AHR in presence of other competitors can inform us 
on mechanisms of interaction with other molecules in vivo. 
3. Indole and other indole-derived molecules have been shown to induce anti-
inflammatory immune responses in hosts. Co-culturing bacterial cells and 
mammalian cells in micro-fluidic devices using bacterial consortia from cecal 
contents would be an interesting step towards studying the effect of multiple de 
novo bacteria-derived metabolites on host cells. This might reveal some new 
signaling pathways that are integral in mediating bacteria-derived signals. 
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